Cancer Immunotherapy Targeting T Cell Costimulatory Molecules by Pardee, Angela D.
  
 
CANCER IMMUNOTHERAPY TARGETING T CELL COSTIMULATORY 
MOLECULES 
 
 
 
 
 
 
 
 
by 
Angela D. Pardee 
B.A., Boston University, 2005 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
the School of Medicine in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2010 
 
   ii 
UNIVERSITY OF PITTSBURGH 
SCHOOL OF MEDICINE 
 
 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
 
Angela D. Pardee 
 
 
 
It was defended on 
September 24, 2010 
and approved by 
Lisa H. Butterfield, Ph.D., Associate Professor, Department of Medicine 
Nick Giannoukakis, Ph.D., Associate Professor, Department of Pathology 
Michael Shurin, M.D., Ph.D., Associate Professor, Department of Pathology 
Angus Thomson, Ph.D., D.Sc., Professor, Department of Surgery 
Simon Watkins, Ph.D., Professor, Department of Cell Biology and Physiology 
 Dissertation Advisor: Walter J. Storkus, Ph.D., Professor, Department of Dermatology 
 
 
   iii 
Copyright © by Angela D. Pardee 
2010 
   iv 
 
According to the American Cancer Society, over 1.5 million new cancer cases will be diagnosed 
this year, a figure that is expected to rise with the aging population. Chemotherapy and radiation 
are the current “gold standards” for cancer treatment, but these therapies are marginally 
effective, toxic, and serve to diminish the quality of life for cancer patients. Immunotherapy 
represents an attractive alternative to these traditional treatment regimens. Despite overwhelming 
evidence that the immune system is capable of recognizing and eliminating tumors, both 
spontaneously and in response to immune-based therapy, such protection is abrogated in the face 
of compensatory immunosuppressive events characteristic of progressive disease. Thus, a major 
goal of novel immune-based therapies is the coordinate silencing of regulatory circuits and 
amplification of protective T cell function. 
While immune modulating reagents that trigger the T cell costimulatory molecules OX40 
and GITR are currently being evaluated in early-phase clinical trials, little pre-clinical 
information is available regarding the efficacy and mechanism(s) of action for these agents in the 
setting of advanced, well-established disease. To further characterize the molecular, cellular, and 
treatment-associated consequences of OX40 and GITR engagement, novel agonistic reagents 
directed against murine OX40 and GITR (ligand-Fc fusion proteins) were recently constructed 
and characterized in vitro. We now show that the growth of well-established, day 17 sarcomas is 
significantly inhibited or ablated by a short course of either treatment, with OX40L-Fc 
CANCER IMMUNOTHERAPY TARGETING T CELL COSTIMULATORY 
MOLECULES 
Angela D. Pardee, Ph.D. 
University of Pittsburgh, 2010
 
   v 
demonstrating superior anti-tumor efficacy over GITRL-Fc at comparable dosing. Both 
treatments were capable of eliminating regulatory T cells within tumors, inducing profound 
proliferation of T effector cells in the tumor-draining lymph node, and promoting the recruitment 
of these expanded effector cells to the tumor microenvironment. However, OX40L-Fc therapy 
mediated additional, T cell-independent effects, including the activation of tumor-localized 
dendritic and endothelial cell subsets. These changes rendered the tumor microenvironment more 
immunogenic and permissive to the infiltration of treatment-induced, protective immune cells. 
The pleiotropic anti-tumor effects demonstrated in this model by OX40L-Fc, and to a lesser 
extent GITRL-Fc, strongly supports the further translation of such modalities into human clinical 
trials, either as single agents or in the context of combinational immunotherapy. 
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1.0  INTRODUCTION 
Developing tumors are typically recognized and eliminated by a protective mechanism of 
immunosurveillance, failure of which results in the prevalence of tumor tolerance over immunity 
(1, 2). The goal of tumor immunotherapy is to break such tolerance and initiate a robust, 
prolonged tumor-specific immune response without the harsh toxicities that traditional cancer 
therapies impart. High-profile accomplishments in the field have recently been made, including 
FDA-approval of the first cellular vaccine for cancer (3), and demonstration that a small minority 
of patients with metastatic melanoma can be, for all intents and purposes, cured upon antibody-
mediated blockade of the T cell inhibitory molecule CTLA-4 (4). Median overall survival in both 
trials, however, was only increased by 4 months. While these milestones should be celebrated as 
proof-of-concept that T cell-based immunotherapy of cancer is feasible and relatively effective 
(compared to standard of care treatment), there is clearly room for improvement. 
Costimulatory members of the tumor necrosis factor (TNF) receptor family, including 
OX40 and GITR, are essential components of functional immunity, regulating T cell survival 
and activation at naïve, effector, and memory stages of the adaptive immune response (5). 
Accumulating pre-clinical data suggests that engagement of costimulatory members of the TNF 
receptor (TNFR) family may counteract tumor-mediated immunosuppression by directly 
reactivating tumor-specific T cells and/or inhibiting dominant suppressive mechanisms that 
prevent T cell effector function(s) in vivo (6). Based on this duality of immunostimulatory 
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function, TNFR-based agonistic modalities, administered alone or in combination with other 
immunotherapies, possess high potential for use in treating cancer, a notion that was recently 
supported by the prioritization of such agents for clinical translation by the National Cancer 
Institute (7). 
1.1 IMMUNOSURVEILLANCE OF CANCER 
1.1.1 Immunosurveillance: a primer 
The theory that pre-neoplastic lesions can be recognized and eliminated by the immune system 
was first proposed by Ehrlich in 1909, and the term immunosurveillance was later coined by 
Burnet and Thomas (1, 8). This theory could not be tested experimentally, however, until our 
understanding of immunobiology had matured and immunodeficient mouse models became 
available. Although early experiments indicated that carcinogen-induced tumors grew 
equivalently in immunocompetent and immunodeficient mice, refuting the cancer 
immunosurveillance hypothesis, it was later determined that these “immunodeficient mice” in 
fact contained natural killer (NK) cells and low frequencies of T cells (9). Years later, 
immunosurveillance became a hot topic again when IFN-γ neutralizing antibodies were found to 
accelerate tumor growth (10), consistent with later observations made in IFN-γ−/− mice (11). 
Perforin, as well as NK and NKT cells, were identified as additional factors integral to protective 
anti-cancer immunity, as perforin- or NK1.1-deficient mice, respectively, developed tumors at 
higher rates than their wild-type counterparts (11, 12). Finally, the most compelling data in 
support of the cancer immunosurveillance hypothesis came when carcinogen-induced tumor 
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incidence was found to be enhanced in Rag-2−/− mice that lack T, B, and NKT cells (13). 
Observational data from humans further supports the existence of a cancer immunosurveillance 
process. Immunosuppressed transplant recipients, for example, exhibit higher incidences of 
cancers of non-viral origin than the general population (14), while the density of tumor-
infiltrating lymphocytes (TIL) is associated with favorable clinical outcome in cancers of various 
histological origins (15-17). In summary, the plethora of experimental data from mice and 
correlative clinical data validate the concept that the immune system can protect against tumor 
growth and progression. 
1.1.2 Elimination 
A series of sequential cellular and molecular events are though to be necessary for the 
recognition and immune-mediated elimination of developing tumors (1, 18). First, the normal 
tissue surrounding cancer cells is disrupted as a consequence of tumor expansion, resulting in the 
subsequent release of “danger” signals (19), which serve as agonists for pattern-recognition 
receptors expressed by cells of the innate immune system (20). A positive feedback system 
between tumor-infiltrating macrophages, dendritic cells (DC) and NK cells then amplifies the 
production of pro-inflammatory cytokines (i.e. type I and II interferons, IL-12) and induce a state 
of acute inflammation (21-23). Next, tumor-infiltrating DC, which are considered professional 
antigen-presenting cells (APC), acquire antigens released by dying tumor cells (24), mature, and 
migrate to the tumor-draining lymph node (TDLN) (25, 26). These mature DC process and 
present tumor antigen in the context of MHC class I molecules via the cross-presentation 
pathway to activate CD8+ cytotoxic T lymphocytes (CTL) (27). Priming of MHC class II-
restricted CD4+ T cells by DC also occurs in the TDLN (28). These activated Th1 CD4+ T cells 
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further amplify the adaptive immune response by “licensing” DC-mediated priming of CD8+ T 
effector cells via CD40/CD40L interactions and the secretion of IFN-γ (29, 30). Efficient T cell 
priming by DC involves two signals: i.) interactions between the T cell receptor (TCR) on T cells 
and MHC-peptide complexes on DC, and ii.) engagement of the costimulatory receptor CD28 on 
T cells with CD80 and CD86 on DC. Additionally, T cell differentiation towards Th1 (pro-
inflammatory) or Th2 (anti-inflammatory) can also be facilitated through provision of a 
polarization signal, or “signal 3” (31). The concept of T cell plasticity has become exceedingly 
complex in recent years, with 7 unique subsets of CD4+ T cells currently defined (32). Finally, 
activated tumor-primed CD4+ and CD8+ T effector cells home to the tumor microenvironment 
(TME) in response to CXCR3 chemokine ligands (CXCL-9, -10 and -11) and carry out their 
tumoricidal activity (33, 34). 
During the effector phase of an anti-tumor immune response, the functions of IFN-γ are 
multi-fold. Produced primarily by CD4+ Th1 cells and NK cells in the TME, IFN-γ exhibits 
potent anti-proliferative (35) and angiostatic (36, 37) effects on tumor cells and surrounding 
structural cells, respectively. Additionally, stimulation of innate immune cells and structural cells 
in the TME by IFN-γ induces the production of CXCR3 ligands (1). CXCL9 and CXCL10 not 
only serve as chemoattractants for T effector cell and NK cell recruitment into tumor lesions, but 
they are also powerful inhibitors of angiogenesis (38). Moreover, IFN-γ enhances the 
immunogenicity of tumor cells by inducing MHC up-regulation and antigen presentation to CTL 
(39). Finally, NK cell and CD4+ T cell “help” appears to potentiate the effector function of CTL 
through their direct production of IFN-γ in tumor lesions (40). 
Cells with cytolytic capability (i.e. NK cells and CTLs) are essential players in the anti-
tumor effector phase (41). Tumor cells commonly down-regulate MHC class I to avoid a CTL 
  5 
attack (42). Ironically, these cells simultaneously up-regulate MHC class I chain-related proteins 
A and B (MICA/B) (43), rendering them susceptible to attack by NK cells, which express the 
MICA/B receptor NKG2D (44). NK cells carry out their cytotoxic effector activity primarily 
through the perforin/granzyme granule exocytosis pathway. In brief, lytic granules containing 
perforin and granzymes are secreted by NK cells upon contact with the target cell. Perforin, a 
membrane-disruption protein, forms pores on the target cell’s plasma membrane, which allows 
the entry of serine proteases known as granzymes. These molecules then initiate a proteolytic 
caspase cascade that results in DNA fragmentation and target cell apoptosis (45). NK cells can 
also induce target cell apoptosis by signaling through TRAIL, an apoptosis-inducing member of 
the TNF superfamily (44). 
The cumulative data from experimental murine tumor models (46-48) and immuno-
monitoring of human cancer patients (16, 49) strongly suggests that CD8+ T cells are integral to 
immune-mediated tumor elimination, perhaps more than any other immune cell subset. In 
contrast to NK cells, CD8+ CTL exert their tumoricidal activity in an MHC class I-restricted 
tumor-specific manner, although their effector functions are similar. CTLs also mediate target 
cell apoptosis through secretion of lytic granules and signaling through an apoptosis-inducing 
member of the TNF superfamily, in this case FasL (45). An additional and significant function of 
CD8+ T cells is the production of IFN-γ, the numerous anti-tumor activities of which are 
described above.  
1.1.3 Tumor antigens 
A requirement for tumor elimination mediated by the adaptive immune system is the existence of 
immunogenic tumor antigens presented in the context of MHC class I molecules. Viral antigens, 
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expressed by virally-induced cancers such as cervical cancer and Burkitt’s lymphoma (50), are 
considered tumor-specific antigens (TSA) because their expression is restricted to cancer cells. 
However, because most human cancers are non-viral in etiology and therefore recognized by the 
immune system as “self,” the ability of humans to mount tumor-specific immune responses 
against such cancers was doubted (51). Following the landmark observation that tumor-specific 
T cell-mediated immunity can spontaneously arise in a small subset of patents (52), the first non-
viral tumor antigen, MAGE-1, was identified by Boon and colleagues (53). Importantly, this 
HLA-A1-restricted antigen was expressed by primary melanoma cells and melanoma cell lines, 
but not normal tissues.  
The evolution of sequencing technologies and cell propagation techniques has allowed 
the characterization of over 1000 human tumor antigens (1). Tumor antigens fall into two broad 
categories: i.) tumor-specific antigens (TSA), which include viral antigens as well as antigens 
that arise as a result of somatic mutations in the cancer cell (i.e. p53 mutations), and ii.) tumor-
associated antigens (TAA), which represent the majority of human tumor antigens. TAAs are 
non-mutated self molecules that are preferentially expressed by cancer cells, but can be 
expressed by normal cells as well (54). Because of the less restricted expression profile of these 
antigens, compared to TSAs, T cell-targeting of TAAs carries a higher risk of correlative 
autoimmunity. TAAs can be further divided into three sub-categories (1): i.) differentiation 
antigens, which are expressed by cancer cells and normal cells of the same origin (i.e. MART-1, 
tyrosinase, gp100), ii.) overexpressed antigens, which are amplified in cancer cells and expressed 
in normal tissues at low levels (i.e. HER-2/neu), and iii.) cancer-testis antigens, which are 
normally expressed only by germ cells in the testis, but are aberrantly expressed by cancer cells 
as a result of genetic instability (i.e. MAGE, NY-ESO-1) (55).  
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Additionally, recent advances by our group and others have indicated that antigens 
expressed by the tumor stroma can serve as valuable targets of anti-tumor T cells. Solid tumors 
(i.e. carcinomas and sarcomas) are comprised of cancer cells and additional non-transformed 
cells of that make up the tumor stroma. Stromal cell subsets include bone-marrow-derived cells 
(i.e. monocytes, granulocytes, lymphocytes), endothelial cells, supporting vascular cells (i.e. 
pericytes), and tissue-associated fibroblasts (56). These stromal cells support tumor cell fitness 
by providing nutrients (i.e. oxygen), growth factors, and cytokines (55). Together, cancer cells 
and the surrounding stroma make up what is known as the tumor microenvironment, or TME 
(57). We have recently demonstrated that prophylactic vaccination against hemoglobin-β, which 
is aberrantly expressed by tumor-associated pericytes, protects mice against subsequent tumor 
challenge (58). Additional “stroma-associated antigens” that have exhibited immunogenicity in 
murine tumors models include fibroblast activation protein (FAP) and vascular-endothelial 
growth factor receptor 2 (FLK-1) (59, 60). Of particular therapeutic significance, it has been 
reported that TAAs can be acquired and cross-presented by the tumor stroma, followed by CTL-
mediated elimination of these TAA-expressing stromal cells (56, 61). Furthermore, cancer cells 
that lost TAA expression (antigen loss variants) were simultaneously eliminated via an unknown 
mechanism when CTL killing of TAA-expressing stromal cells occurred. Given that tumor cells 
commonly lose MHC class I expression (42), while stromal cells do not, targeting of stroma-
associated antigens or TAA cross-presented by stromal cells represents an attractive 
immunotherapeutic approach. 
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1.2 MECHANISMS OF IMMUNE ESCAPE 
Needless to say, the cancer immunosurveillance process is not always effective, and clinically-
apparent disease can develop. Although immune evasion was not designated by Hanahan and 
Weinberg (55) ten years ago as a “hallmark of cancer,” likely because the cancer 
immunosurveillance theory remained controversial at the time, the ability of tumors to evade an 
immune response is now recognized as an essential characteristic of malignant disease. Tumors 
employ a variety of mechanisms to evade the immune response, both locally in the tumor 
microenvironment (effector phase tolerance) and distally in the TDLN (suboptimal T cell 
priming) (2, 62). The concepts of inadequate tumor cell recognition (immunologic ignorance), 
intrinsic T cell dysfunction, and extrinsic suppression of T cells by immunoregulatory molecules 
and cells will now be discussed. 
1.2.1 Immunologic ignorance 
Human tumors that are not eliminated in the process of immunosurveillance or as a result of 
therapy can remain in a state of dormancy that can last decades (63). Indeed, cancer recurrence 
following long periods of remission is commonly observed (64, 65). Moreover, cancers have 
been inadvertently transferred from donor to recipient upon organ transplantation, even when the 
donors had been diagnosed as cancer-free for many years prior to transplantation (66). Tumor 
dormancy can also be experimentally induced in mice, and it has been demonstrated that 
sculpting of the tumor cell repertoire by the immune system occurs during this “equilibrium 
phase” (63, 67). In one study, tumors were grown in either immunocompetent (wild-type) or 
immunodeficient (RAG-2−/−) mice and then transplanted into wild-type mice. Tumors isolated 
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from wild-type mice grew progressively in the recipients, while tumors that were grown in 
immunodeficient more were rejected, suggesting that these tumors are more immunogenic than 
those isolated from wild-type controls (13). The concept that the immune system eliminates 
highly-immunogenic tumor cells and spares those of low immunogenicity has been termed 
“immunoediting” (1). The end product of this process, however, is the outgrowth of poorly-
immunogenic tumor cell variants that can escape immune recognition. 
Additional mechanisms inhibit the ability of the immune system to recognize tumor cells. 
As noted above, tumor cells commonly down-regulate MHC class I (42), but components of the 
antigen processing and presentation machinery (i.e. β2-microglobulin and TAP1) in these cells 
can also be dysregulated (68). Insensitivity of tumor cells to the many effects of IFN-γ signaling 
can also develop during the course of disease progression (69). Finally, tumor cells can “hide” 
from an NK cell attack via shedding of MICA/B, molecules that serve as ligands for the 
activating NK cell receptor NKG2D, thereby preventing MICA/B-NKG2D interactions and 
protecting against NK cell-mediated tumor lysis (70). 
1.2.2 T effector cell anergy/dysfunction 
T effector cell hyporesponsiveness, another major barrier to effective anti-tumor immunity, 
occurs through: i.) the induction of systemic TAA-specific T cell anergy, and ii.) T effector cell 
dysfunction upon infiltration of tumor lesions. T cell anergy, a consequence of inefficient 
priming, is characterized by an inability to respond to TCR stimulation, resulting in impaired T 
cell proliferation and/or effector function upon MHC-peptide engagement (71). It has been 
proposed that T cell anergy represents a significant barrier to spontaneous and therapeutic anti-
tumor immunity (72). The activation of tumor-specific T cells is dependent on cross-presentation 
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of tumor antigen by APC in the TDLN, rather than through direct presentation by tumor cells 
themselves (73), indicating that dysfunctional APCs are responsible for the generation of 
systemic TAA-specific anergy (74). Indeed, poorly-immunogenic, or “tolerogenic,” DC have 
recently been characterized and determined to play an important role in this process (75, 76). 
These DC exhibit an immature phenotype (i.e. low surface expression of CD40 and CD86) and 
produce minimal amounts of IL-12 (77, 78). Additionally, secretion of the enzyme indoleamine 
2,3-dioxygenase (IDO) by DC at the time of T cell priming results in durable antigen-specific 
anergy (79). 
Moreover, T effector cells that are sufficiently-activated in the TDLN can lose 
functionality upon infiltration of tumor lesions. T cell-intrinsic dysfunction, characterized by 
suboptimal granule exocytosis, cell cycle arrest, and defective cytokine secretion, has been 
attributed to tumor-induced inhibition of proximal TCR signaling (80-82). TIL hypo-
responsiveness may also be a consequence of prolonged antigen signaling within the tumor mass 
and subsequent T cell “exhaustion” (83). Indeed, TIL that were isolated and expanded ex vivo 
displayed optimal anti-tumor activity when the time in culture (i.e. rounds of in vitro stimulation) 
was minimized (84). 
1.2.3 Active suppression of T effector cells 
Tumor cells themselves employ an expansive arsenal of weapons to evade an immune attack, 
including surface expression of inhibitory molecules and secretion of immunosuppressive 
cytokines (2). Although structurally related to the costimulatory receptor ligands CD80/B7.1 and 
CD86/B7.2, PD-L1/B7-H1 and B7-H4 send inhibitory signals upon T cell engagement and are 
therefore referred to as co-inhibitory molecules (85, 86). Elevated expression of both PD-L1 and 
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B7-H4 on tumor cells has been reported and is associated with poor clinical prognosis (87, 88). 
Tumor cells are also known to produce high levels of the pleiotropic immunosuppressive 
cytokines IL-10 (89) and TGF-β (90, 91). 
Contrary to the anti-tumor properties of lymphoid and myeloid immune cells discussed 
above, immune-suppressive subsets of these cells that exert pro-tumorigenic activity have also 
been identified. At this point, CD4+ regulatory T cells (Treg) and myeloid-derived suppressor 
cells (MDSC) are the best characterized of these suppressor cells. Naturally-occurring 
CD4+CD25+ Tregs, which develop in the thymus with specificity to self antigen, are identified 
by constitutive expression of the transactivator protein Foxp3 and represent 5-10% of peripheral 
CD4+ T cells (92, 93). Once activated by TCR engagement, natural CD4+CD25+ Tregs suppress 
non-specifically and through direct cell-to-cell contact that may involve surface-bound TGF-β 
(94, 95). Regulatory T cells can also develop in the periphery from naïve CD4+ T cells after 
chronic stimulation by immature DC or in the presence of IL-10 or TGF-β (96, 97). These 
peripherally-induced Tregs appear to function via IL-10 secretion (98). In tumor-bearing hosts, 
Tregs exert their immunosuppressive activity in both the TDLN and TME. In murine models, 
TDLN Tregs inhibit anti-tumor T effector cell priming (99), and have been found to increase in 
frequency and suppressor activity over the course of disease progression (100). In the TME, Treg 
induction, expansion, and/or recruitment all contribute to the abrogation of anti-tumor immunity. 
For example, increased proportions of TGF-β and IL-10-secreting Tregs capable of suppressing 
CTL proliferation were observed in late-stage cancer patients (101), while Curiel and colleagues 
reported preferential migration of Foxp3+ Tregs into ovarian tumors and ascites, which correlates 
with poor prognosis (102). In addition to TGF-β and IL-10 secretion, proposed suppressive 
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mechanisms of these intratumoral Tregs include competitive consumption of IL-2, perforin- or 
granzyme-dependent killing of T effector cells, and induction of tolerogenic DC (103). 
Additional inhibitory-type cells that accumulate dramatically in tumors include myeloid-
derived suppressor cells (MDSC), a heterogeneous population that is identified by CD11b+Gr-1+ 
co-expression and exhibit properties of both macrophages and granulocytes (104). Since these 
cells phenotypically and functionally resemble alternatively activated, or M2, macrophages, it is 
currently unknown whether MDSC and M2 macrophages represent distinct cellular subsets or 
are a result of myeloid cell plasticity (105). Regardless, CD11b+Gr-1+ cells isolated from tumor-
bearing mice potently inhibit anti-tumor T effector cell immunity (106), primarily through the 
production of enzymes (i.e. arginase-1) that interfere with T cell amino acid metabolism (107). 
Correlative clinical data also implicates a key role for these cells in tumor immune evasion (108). 
1.2.4 Impaired tumor homing 
In addition to the ability of tumor microenvironmental factors to disable anti-tumor T cell 
activity, the TME can physically impede the migration and infiltration of effector cells. A clear 
correlation between T cell infiltration of tumors and overall survival has been routinely observed 
(17, 109). Circulating T cells extravasate into peripheral tissues through recognition of adhesion 
molecules, including ICAM and VCAM, which are up-regulated by vascular endothelial cells 
(VEC) in response to inflammatory conditions, followed by chemokine-mediated migration to 
the target site (110). This process is complicated in the cancer setting, however, due to tumor-
induced vascular alterations and limited chemokine and adhesion molecule expression. The 
vasculature of solid tumors is characterized by disorganized, tortuous vessels that restrict the 
infiltration of nutrients, oxygen, therapeutic drugs, and tumor-primed T cells (111). The 
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importance of IFN-γ-inducible chemokine (i.e. CXCL9/Mig and CXCL10/IP-10) production in 
the TME has also been demonstrated, as high IP-10 levels correlated with favorable prognosis of 
patients with uterine/cervical cancers (112). Strategies to “normalize” the tumor vasculature and 
induce chemokine and adhesion molecule up-regulation have shown efficacy in pre-clinical 
models (113-115). 
1.3 CANCER IMMUNOTHERAPY 
Recent conceptual advancements have improved our understanding of tumor biology and the 
paradoxical effects of the immune system in the setting of cancer. These advancements have also 
facilitated the evidence-based design of a plethora of novel immunotherapeutic strategies, the 
goals of which are to: i.) enhance suboptimal host immunity through administration of activation 
stimuli or preformed tumor-specific antibodies or T cells (i.e. passive immunotherapy), ii.) 
generate de novo tumor-specific T cell immunity through active immunization, and/or iii.) 
counteract the immunosuppressive mechanisms discussed above. Ultimately, it is expected that 
optimal therapeutic benefit will require treatment regimens that engage multiple immune effector 
mechanisms. Immunotherapeutic modalities that have been FDA-approved or are in late-phase 
clinical development will now be addressed. 
1.3.1 Passive Immunotherapy 
Passive immunotherapy is an umbrella term for a variety of treatment modalities, including 
tumor-targeting mAbs, immune adjuvants, cytokine therapy, immune-modulating mAbs, and 
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adoptive T cell therapy (116). Monoclonal antibody (mAb) therapy is the most widely used form 
of passive cancer immunotherapy. These mAbs target molecules preferentially expressed on the 
surface of tumor cells in an MHC-unrestricted manner. Several FDA-approved mAbs target 
proteins that are expressed by hematologic malignancies (i.e. leukemias and lymphomas), 
including CD52, CD33, and CD20. Solid tumors can also be treated by mAb therapy. FDA-
approved mAbs against EGFR and HER2/neu expressed by tumors of epithelial origin are 
indicated for use in breast and colorectal cancers. Moreover, the vasculature of solid tumors can 
be targeted by anti-VEGF mAbs. Tumor-targeting mAbs can exert their effector function 
through several mechanisms, including signaling blockade, complement activation, and 
antibody-dependent cellular cytotoxicity, although the activity of each reagent is dependent on 
the Fc region of the antibody (116). 
Systemic treatment with cytokines, including IL-2 and IFN-α, has been approved for 
clinical use. Although the exact anti-tumor function of these cytokines in vivo is unclear, severe 
adverse events are common and often dose limiting (116). Novel approaches to cytokine-based 
therapy include conditional cytokine expression by gene-engineered dendritic cells (117). 
The primary goal of next-generation passive immunotherapies is to abrogate tumor-
induced immunosuppression. As described above, blockade of the T cell inhibitory molecule 
CTLA-4 in a Phase III clinical trial improved overall survival of patients with metastatic 
melanoma (4). FDA approval of this reagent is expected within a year. Antibody-mediated 
blockade of PD-1, an additional T cell inhibitory molecule, has also demonstrated therapeutic 
benefit in early-phase clinical trials, but unlike anti-CTLA-4, only minor adverse events were 
reported upon PD-1 blockade (118). Moreover, Treg-depleting reagents, such as denileukin 
diftitox (Ontak), that target the constitutively-expressed molecule CD25, have been shown to 
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effectively eliminate circulating Tregs without coordinate depletion of activated, CD25-
expressing T effector cells (119). 
1.3.2 Active Immunotherapy 
Active immunotherapy is defined as the de novo generation of tumor-specific immunity, 
mediated primarily through vaccination. Two prophylactic vaccines against virally-induced 
cancers have been approved by the FDA: i.) the HBV vaccine to prevent the development of 
hepatocellular carcinoma, and ii.) the HPV vaccine against cervical cancer, but also additional 
forms of genital epithelial tumors and some forms of head and neck cancer (116). However, most 
human cancers are non-viral in etiology and express patient-specific antigens. Prophylactic 
vaccination against these spontaneously-occurring cancers is therefore unrealistic. Instead, 
several therapeutic vaccination strategies have been developed, including purified peptide or 
protein vaccines, tumor cell vaccines, and DC vaccines (120). 
As mentioned previously, the first cellular vaccine for cancer, sipuleucel-T (Provenge), 
was approved earlier this year and is indicated for castration-resistant prostate cancer. This 
product has been marketed as a DC vaccine, although it is actually a mixture of autologous 
lymphocytes and myeloid cells that are loaded ex vivo with a prostate-associated antigen and 
then re-infused into patients (3). 
Whole tumor cell vaccines have the advantage of providing multiple tumor antigens 
Several types of these vaccines are currently in late-phase clinical development, including 
GVAX, which is comprised of cultured tumor cell lines (allogeneic), irradiated and engineered to 
secrete the DC growth-promoting cytokine GM-CSF (121). Finally, peptide-based vaccines, 
targeting TAAs such as MAGE-A3 and NY-ESO-1, may be the most cost-effective and least 
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labor-intensive of these vaccination strategies, but clinical benefit has been limited (116). Next-
generation approaches may involve co-administration of adjuvants, including CpG 
oligodeoxynucleotides (TLR9 agonists), which are expected to enhance the immunogenicity of 
peptide vaccines (122).  
1.4 COSTIMULATORY TNFR FAMILY 
Costimulation is classically defined as the engagement of receptors secondary to T cell receptor 
(TCR) signaling that functions to lower the activation threshold of naïve T cells (123, 124). The 
primary costimulatory receptor on T cells is CD28, which upon binding of its ligands B7.1/CD80 
or B7.2/CD86 initiates high-level IL-2 production and clonal T cell expansion. Additional 
costimulatory molecules, including members of the TNF receptor family, function subsequent to 
CD28 engagement to enhance the activation, survival, and differentiation of T effector and 
memory cells (5). Unlike CD28, which is constitutively expressed by T cells, TNFR 
costimulatory molecules, including 4-1BB/CD137, OX40/CD134, GITR, and CD30, are up-
regulated shortly after activation and down-regulated soon thereafter. TNFR ligands are 
biologically active as trimers, which induce corresponding trimerization of their receptors upon 
binding. This has been observed for OX40 and GITR ligation in both mouse and human cells (5). 
Recently it was reported that murine GITR ligand (GITRL) may exert stronger activity when in a 
dimer conformation (125), while human GITRL can exist and signal effectively in multiple states 
of oligomerization (126), suggesting that structural diversity can exist among TNFR ligands. 
Upon ligand engagement, multiple TNF receptor-associated factor (TRAF) molecules are 
recruited to the intracellular domain of costimulatory TNF receptors and initiate JNK, p38, and 
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NF-κB signaling pathways (5). Alterations in signaling cascades elicited by various TNFR 
family members may be attributed to divergent affinities for TRAF proteins and the existence of 
at least six unique TRAF isoforms. 
1.4.1 OX40 
OX40 is restricted to naturally-occurring Treg and activated T effector cells (preferentially 
CD4+), with expression typically peaking 48-72 hours after TCR engagement (5, 127, 128). 
Administration of agonist OX40 mAb enhances the primary clonal expansion of both CD4+ and 
CD8+ TCR transgenic T cells in vivo (129-131), perhaps due to the OX40-dependent down-
regulation of the inhibitory costimulatory receptor CTLA-4 (132). While early studies suggested 
that OX40 ligation preferentially yielded Type-2 effector cytokine production by CD4+ T cells, 
accumulating evidence now indicates that OX40/OX40L interactions enhance ongoing Type-1 or 
Type-2 responses and do not bias the functional polarity of CD4+ T effector cells (5). 
Experimentally-induced CD4+ T cell anergy can also be abrogated by OX40 engagement (133), 
and it has recently been reported that genetic mutations leading to OX40 over-expression 
predispose individuals to systemic lupus erythematosus (134), suggesting that OX40 ligation can 
potently reverse established T cell tolerance. 
Costimulatory TNFR signaling is also thought to play a dominant role in T cell survival 
and the generation of memory following initial clonal expansion; this topic has been 
comprehensively discussed in recent reviews (5, 135). Consistent with this notion, the primary 
role of OX40 signaling appears to involve the extension of T cell survival following initial clonal 
expansion and differentiation into T cell memory. OX40-deficient CD4+ and CD8+ T cells 
undergo premature apoptosis in vivo (131, 136), while agonist mAb-mediated OX40 
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costimulation prolongs CD8+ T cell survival that can be further augmented by co-treatments 
incorporating 4-1BB agonist mAb (137, 138). Furthermore, the lack of OX40 signaling impairs 
the maintenance of CD8+ memory and CD4+ T effector but not central memory T cells (139, 
140). OX40/OX40L interactions may help to establish a “CD4 memory niche” involving the IL-
7-dependent up-regulation of OX40 expression on CD4+ T cells (135). Finally, the role of OX40 
in both natural and inducible regulatory T cells (nTreg and iTreg, respectively) has recently 
received significant attention (141). OX40 signaling does not appear to play a significant role in 
the peripheral maintenance of nTreg, as similar numbers of these cells are observed in the 
peripheral tissues of OX40−/− and wild-type mice (142). OX40 ligation on nTreg can induce their 
proliferation, but it has not been conclusively demonstrated that these expanded nTreg retain 
their suppressor function. It does appear, however, that OX40 engagement may antagonize nTreg 
function in the absence of cell proliferation (142, 143). Naïve CD4+CD25− T cells can also 
acquire regulatory activity upon culture with low dose antigen and TGF-β, for example (144). 
Recent reports suggest, however, that the induction of Foxp3 gene expression can be inhibited 
through OX40/OX40L interactions that may involve the manipulation of TGF-β signaling 
pathways (142, 144, 145). Alternatively, OX40 signaling may indirectly subvert Treg function 
by rendering T effector cells refractory to the action of Treg (143). Hence, OX40 appears to 
interface a number of divergent mechanisms that limit Treg-mediated immune suppression, 
including the prevention of iTreg generation, direct inhibition of nTreg function, and by 
conferring resistance of effector cells to Treg-dependent inhibition. 
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1.4.2 GITR 
GITR and its human ortholog AITR are expressed on nTreg and activated B cells, macrophages, 
DC, NK cells, and effector T cells (5, 127, 146). On T effector cells, GITR is up-regulated earlier 
than OX40, peaking approximately 24 hours after T cell activation. Interestingly, it was recently 
shown that GITR expression is induced in Treg by a complex between Foxp3 and the 
transcription factor NFAT (147), whereas in activated T effector cells NFAT inhibits while 
NFκB induces GITR up-regulation (148), suggesting that distinct regulatory mechanisms control 
GITR expression in different cell subsets. Similar to OX40, GITR ligation enhances primary T 
cell expansion and effector cytokine secretion in the presence of low-dose antigen (149, 150). 
Likewise, GITR/GITRL interactions can reverse T cell tolerance via a Treg-independent 
mechanism, as depletion of CD25hi Treg does not yield a similar phenotype (151). GITR 
engagement has also been reported to sustain the survival of activated T cells and to prevent 
activation-induced cell death (AICD) in wild-type versus GITR−/− T cells (152, 153). Moreover, 
IL-15 appears to be important for GITR-based maintenance of the CD8 memory pool in 
particular, as this cytokine induces GITR up-regulation and may contribute to a unique “CD8 
memory niche” (135). 
Despite accumulating evidence that GITR signaling directly augments the immune 
function of T effector cells, considerably more attention has been paid to investigating the impact 
of GITR on regulatory T cell activity. In this regard, only a limited role for GITR in the 
development, maintenance, and function of nTreg has been shown in GITR−/− mice (154). As 
with OX40, GITR ligation can induce the proliferation of both murine and human nTreg, but 
conflicting reports exist regarding the function of these expanded Treg (155-157). A recent study 
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by Wang and colleagues suggest that GITR engagement can prevent the conversion of naïve 
CD4+ T cells into Foxp3+ iTreg in the presence of TGF-β (158). Although GITR/GITRL 
interactions may contribute directly to the regulation of Treg subsets, elegant experiments from 
the Shevach group using combinations of wild-type or GITR−/− effector cell/Treg co-cultures 
indicate that effector T cells are the primary target of GITR costimulation (154, 159). While 
GITR−/− CD4+CD25+ Treg exhibit similar suppressive capacity as wild-type Treg, the 
proliferation of GITR−/− but not wild-type CD4+CD25− effector T cells is inhibited upon 
stimulation with GITR agonist mAb, suggesting that GITR ligation renders effector T cells 
resistant to Treg-mediated suppression. Finally, although GITR is expressed by activated human 
NK cells, it is unclear whether GITR signaling mediates activating or inhibitory signals in these 
cells (160, 161), despite clear evidence that GITR stimulation enhances the proliferation and 
effector cytokine production of murine NKT cells in vitro and in vivo (162). 
1.5 THERAPEUTIC COSTIMULATORY TNFR AGONISTS 
The National Cancer Institute recently published a priority list of immunotherapy agents with 
anticipated anti-tumor potential, placing an emphasis on agents that are not commercially 
available or fully-developed for testing in humans at this time (7). Agonist antibodies targeting 
OX40 and GITR, a type of passive immunotherapy, were among the 20 agents emphasized from 
a list of over 100 novel modalities. Based on the aggregate conclusions from a large volume of 
murine tumor studies, described below, it is clear that TNFR-targeting therapeutics have 
tremendous potential to augment anti-tumor immunity and ultimately, the survival of cancer 
patients. Contrary to the severe adverse events reported from clinical trials of CD28 agonistic 
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and CTLA-4 blocking mAbs (163, 164), the efficacy of TNFR-based therapy has been 
consistently demonstrated in pre-clinical tumor models in the absence of pathologic 
inflammatory responses, likely attributable to the action of inducible rather than constitutively 
expressed TNF receptors on T cells (165). 
1.5.1 OX40 
Most mechanistic studies in murine tumor models have utilized depleting antibodies specific for 
various immune cell subsets and immunodeficient mice to define requisite cell types linked to 
drug impact. For example, a number of groups have reported that the therapeutic efficacy of 
OX40 agonists appears to rely heavily on CD8+ T cells, as tumors rapidly progress upon 
depletion of this immune cell subset (166-172). CD4+ T cells appear to play an even greater role 
in treatment outcomes associated with OX40-based therapy (166-170). Pan and colleagues 
reported that co-administration of agonist OX40 significantly enhances the tumor infiltration and 
ex vivo tumoricidal activity of CD8+ T cells isolated from mice treated with anti-4-1BB and IL-
12 gene therapy, while CD4+ T cell depletion abrogates this effect (173). Moreover, a recent 
study using OVA-transduced tumors and adoptive transfer of OX40-stimulated OT1 (anti-OVA 
CD8+) T cells suggests that the accumulation of Type-1, tumor-specific CD8+ T cells in the 
tumor microenvironment is dependent on endogenous CD4+ T cells, as CD8+ TIL are absent in 
homologous models established in MHC Class II-deficient (CD4+ T cell-deficient) mice (174). 
OX40-mediated signals thus appear to augment the helper function of CD4+ T cells, thereby 
indirectly promoting the optimal effector function of anti-tumor CD8+ T cells. However, this 
notion has not been universally observed in experimental models, since OX40-dependent, CD8+ 
T cell-mediated therapeutic efficacy is preserved in CD4+ T cell-deficient mice (131, 175). This 
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suggests that OX40-associated signals may directly result in the stimulation of CD8+ T cells 
under such conditions, or that an alternative cell type may provide OX40-dependent “help” to 
developing CD8+ T cells in the CD4-deficient host. Support for the latter was recently provided 
by Zaini and colleagues, who found that OX40-mediated therapy of B16 melanoma is abrogated 
in NKT cell-deficient mice (170). In this regard, it is important to note that although OX40 
expression is thought to be restricted to T cells, 20% of OX40+ TIL in this model exhibit an NKT 
cell phenotype. The authors propose that OX40L-transduced DC activate tumor-localized NKT 
cells to secrete IFN-γ, which acts to facilitate the priming of Type-1 T cells via DC maturation 
and functional “licensing” (176) or the direct differentiation of CD8+ T effector cells (40, 177). 
Two additional recent studies suggest that OX40 agonists may abrogate tumor-induced 
immunosuppression by either preventing the conversion of naïve CD4+ T cells into Foxp3+ Treg 
(172), or by limiting the frequency and function of MDSC (178). 
A variety of OX40-targeted modalities exist as potential therapeutic agents, including 
agonist antibodies, ligand-Fc fusion proteins (179), ligand-expressing viral vectors, and ligand-
transduced DC or tumor cell vaccines (6). Weinberg and colleagues initially assessed the 
therapeutic efficacy of agonist OX40 mAb and recombinant OX40L-Fc fusion protein, 
concluding that when administered early after tumor inoculation (i.e. by day 3), overall tumor-
free survival was significantly enhanced in model systems employing a range of tumor cell lines 
exhibiting variable inherent immunogenicities (180). Using a clinically-relevant model of tumor 
antigen tolerance, transgenic neu-N mice bearing established neu-expressing tumors were 
immunized with GM-CSF-transduced versions of the same tumor as a vaccine (175). Notably, 
enhanced survival of these mice could only be achieved when OX40 mAb was co-administered 
along with the vaccine. 
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A substantial literature exists regarding the expression of OX40 in cancer patients (180-
182). For example, OX40 was found to be expressed by approximately 30% of TIL and draining 
lymph node cells in patients with head and neck squamous cell carcinoma (HNSCC) or 
melanoma (183). Furthermore, high levels of OX40 expression in the TIL of colorectal cancer or 
melanoma patients have been positively-correlated with prolonged patient survival (184, 185). 
Initial screening of an agonist OX40 mAb of murine origin in nonhuman primates revealed no 
overt toxicities despite its potent immunostimulatory properties, i.e. the induction of long-lived 
anti-SIV humoral and T cell responses (186). In addition, a recombinant human OX40L-Fc 
fusion protein has recently been developed that appears capable of stimulating peripheral blood 
T cells in a manner comparable to that noted for agonist mAb (187). A phase I dose escalation 
trial was recently conducted with the murine antibody administered within a five day window 
(188). An extended treatment period was unfeasible due to the generation of human anti-murine 
immunity (i.e. HAMA responses). Although none of the treated patients exhibited tumor 
regression that met the criteria for partial response, 2- to 4-fold increases in CD4+Foxp3− and 
CD8+ T cells, as well as NK cells, were observed in the peripheral blood of these patients, 
demonstrating for the first time that OX40-based therapy can augment the adaptive immune 
response in humans.  
1.5.2 GITR 
Because GITR was characterized more recently than OX40, it is not surprising that substantially 
less data exists regarding the functional mechanisms and therapeutic efficacy of GITR agonists 
in pre-clinical tumor models (159). Ramirez-Montagut et al. showed that GITR-mediated tumor 
rejection is abrogated upon depletion of CD4+, CD8+, and NK1.1+ cell subsets and in mice 
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deficient in expression of IFN-γ and FasL (189), consistent with results reported by other groups 
using different tumor models (190-192). Treatment of progressing CT26 colon carcinomas with 
agonist GITR mAb led to increased numbers of activated CD4+ T cells, CD8+ T cells, and NK 
cells in the tumor-draining lymph nodes (191). However, this effect was abrogated when CD4+ T 
cells were depleted prior to treatment, indicating that CD4+ T cells play an indispensable role in 
the GITR-dependent priming of therapeutic anti-tumor CD8+ T cells and NK cells. Not 
unexpectedly, increased numbers of Foxp3+ Treg are observed in the spleen and tumor-draining 
lymph nodes of GITR-treated mice (189, 191), yet despite the ability of these Treg to secrete IL-
10, responder anti-tumor CD4+CD25− T cells in these animals appear refractory to Treg-
mediated suppression (191). This observation is likely due to the direct costimulatory effect of 
GITR ligation on CD4+ T effector cells, rather than via the abrogation of Treg function (154). 
Further support for this conclusion is provided by studies performed by Ramirez-Montagut and 
colleagues, who reported that GITR-mediated tumor rejection is enhanced by CD25 depletion, 
indicating that the abrogation of Treg function is not the primary mechanism of GITR-based 
therapy (189). Thus, despite the availability of only a limited data set, GITR agonists appear to 
foster anti-tumor immunity in vivo by primarily targeting fully-differentiated CD8+ T cells and 
by augmenting the ability of CD4+ T helper cells to activate secondary waves of tumoricidal T 
cells. 
The agonist GITR mAb, clone DTA-1, has been the most common GITR-stimulating 
reagent utilized in murine tumor models to date (6). BALB/c mice treated with DTA-1 within 8 
days of syngeneic MethA fibrosarcoma inoculation rapidly reject their tumors and exhibit 
specific resistance to tumor re-challenge (190). GITRL-Fc fusion proteins have also 
demonstrated potent agonist activity in Colon 26 (colorectal carcinoma) and RENCA (renal 
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carcinoma) models (192). Similarly, intratumoral injection of recombinant adenovirus encoding 
GITRL leads to significant inhibition of poorly-immunogenic B16 melanoma growth in 
C57BL/6 mice (193). 
Recent reports suggest that human tumors are enriched in CD4+ TIL expressing a 
CD25hiFoxp3+ phenotype, consistent with Treg cells (194). Such Treg also express GITR and 
exhibit strong suppressor function ex vivo, mediated primarily through IL-10 and TGF-β, while 
Treg in the peripheral blood of patients do not express GITR and exhibit minimal suppressor 
activity (194). Tumor-localized GITR+ Treg may thus be more sensitive to GITR ligation than 
circulating Treg. One mechanism that tumor cells employ to evade immune-mediated destruction 
is the down-regulation or “shedding” of costimulatory receptors and the subsequent induction of 
tumor-specific T cell anergy (195, 196). In fact, soluble tumor-shed GITRL has been reported in 
the sera of patients with various malignancies but not healthy controls (197, 198), where it is has 
been shown to blunt the function of NK cells (198, 199). However, GITR engagement activates 
human T lymphocytes in vitro (126), suggesting that GITRL signals may only be inhibitory to 
NK cell-mediated, rather than T cell-mediated anti-tumor immunity. While clinical-grade GITR 
agonists are in their early stages of development, a fully humanized agonist GITR mAb, 
TRX518, has recently been developed by Tolerx Inc. (Cambridge, MA, USA). Initial 
characterization studies indicate that TRX518 is agonistic for human PBMC in vitro and that it 
fails to bind Fc receptors, thus limiting the theoretical likelihood of antibody- or complement-
mediated deletion of GITR+ cells in vivo (200). 
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1.6 STATEMENT OF THE PROBLEM 
Despite the induction of potent anti-tumor immunity by certain immunotherapy regimens in 
murine tumor models, the results of large, randomized trials of these therapies have generally 
been disappointing (i.e. low objective clinical response rates) (201). One key factor involved in 
these high clinical attrition rates is the use of poorly predictive animal models. Although 
transplantable murine tumors are widely used for experimental immunotherapy studies, most 
treatments are initiated within the first week following tumor inoculation and appear to induce 
immune-based tumor rejection (202). However, when these same therapies were administered to 
mice bearing established tumors (i.e. day 10 post-tumor inoculation), therapeutic benefit was 
completely abolished (202). In order to maximize the likelihood that our results would have 
some predictive value for efficacy in patients, a primary objective of our study was to test the 
efficacy of our costimulatory therapies in the setting of well-established tumors. 
The anti-tumor efficacy of agonistic mAbs towards OX40 and GITR has already been 
widely explored in numerous murine tumor models (6). However, recombinant TNFR ligand-Fc 
fusion proteins serve as an attractive alternative to agonist antibodies, given the comparable or in 
some cases enhanced degree of efficacy observed for ligand-Fc reagents and agonist antibodies 
in mouse models (171, 192). Due to their lower avidity and bioavailability, ligand-Fc fusion 
proteins may also represent a safer alternative to costimulatory agonist antibodies, which can 
elicit significant collateral toxicity (203). Our initial aim, therefore, was to assess the relative 
therapeutic efficacy of OX40L-Fc and GITRL-Fc reagents in the well-established disease setting. 
Although T cell costimulatory agonists targeting OX40 and GITR are currently being 
evaluated in early-phase clinical trials, the mechanism(s) through which such reagents function 
remain controversial, particularly for advanced-stage disease. This problem is considerable, as 
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the rational design of combinational therapies is unfeasible without knowledge of the 
mechanistic activity of these reagents. For example, combination of two therapies with over-
lapping mechanisms would result in a lack of synergistic benefit (in addition to the waste of 
resources and unnecessary burden to patients and clinical personnel). Through a longitudinal 
analysis of treatment-induced alterations in both the tumor-draining lymph node and the tumor 
microenvironment, we were able to identify the molecular and cellular alterations associated 
with the anti-tumor efficacy of therapies based on the use of OX40L-Fc and GITRL-Fc reagents. 
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2.1 ABSTRACT 
Little preclinical modeling currently exists to support the use of OX40 agonists as therapeutic 
agents in the setting of advanced cancers, as well as, the mechanisms through which therapeutic 
efficacy is achieved. We demonstrate that treatment of mice bearing well-established day 17 
sarcomas with a novel OX40 ligand-Fc fusion protein (OX40L-Fc) resulted in tumor regression 
or dormancy in the majority of treated animals. Unexpectedly, dendritic cells (DC) in the 
progressive tumor microenvironment (TME) acquire OX40 expression and bind fluorescently-
labeled OX40L-Fc. Furthermore, longitudinal analyses revealed that DC become enriched in the 
tumor-draining lymph node (TDLN) of both wild-type and Rag−/− mice within three days after 
OX40L-Fc treatment. By day 7 after treatment, a significant expansion of CXCR3+ T effector 
cells was noted in the TDLN, and by day 10 post-treatment, Type-1 polarized T cells exhibiting a 
re-activated memory phenotype had accumulated in the tumors. High levels of CXCL9 (a 
CXCR3 ligand) and enhanced expression of VCAM-1 by vascular endothelial cells (VEC) were 
observed in the TME early after treatment with OX40L-Fc. Notably, these vascular alterations 
were maintained in Rag−/− mice, indicating that the OX40L-Fc-mediated activation of both DC 
and VEC occur in a T cell-independent manner.  Collectively, these findings support a paradigm 
in which the stimulation of DC, T cells and the tumor vasculature by an OX40 agonist 
dynamically orchestrates the activation, expansion and recruitment of therapeutic T cells into 
established tumors. 
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2.2 INTRODUCTION 
As tumors develop and progress, a number of regulatory mechanisms are responsible for 
maintaining immune tolerance in the tumor microenvironment (TME). Poor tumor homing and 
penetration of T effector cells, a consequence of aberrant vasculature and limited chemokine and 
adhesion molecule expression in the TME (113, 204), is one major barrier to anti-tumor 
immunity (15). Furthermore, tumor-specific T cells that effectively infiltrate tumors may be 
rendered inactive by soluble factors and inhibitory signals associated with tumor cells and 
through the negative impact of both myeloid- and lymphoid-derived suppressor cells (2, 205). 
While systemic immunity may be affected to a variable degree, immune suppression is typically 
most profound within the TME, with tumor-infiltrating lymphocytes (TIL) exhibiting severe 
deficiencies in CD8+ T cell-mediated cytotoxic function (206). In murine tumor models, TIL 
dysfunction becomes pronounced only at later stages of solid tumor growth, at which point a 
mature tumor stroma comprised of both bone marrow- and non-bone marrow-derived cells has 
been established (56, 207). 
Given the perceived importance of T cell-mediated immunity underlying effective 
immunotherapy (41) and better clinical outcome (15), substantial emphasis has recently been 
placed on the development of treatment modalities that are capable of restoring T cell function 
and enhancing tumor penetration in the tumor-bearing host. In particular, immune-stimulating 
agents that target the costimulatory TNF receptor (TNFR) family member OX40, have 
demonstrated anti-tumor efficacy in pre-clinical models (165). Costimulatory members of the 
TNFR family are up-regulated shortly after TCR engagement on naïve and antigen-experienced 
cells, where they serve as key modulators of cell activation, survival, and differentiation (5, 135). 
OX40 is expressed by activated T effector cells and OX40-mediated signals provided during 
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priming regulate CD4+ and CD8+ T cell activation and clonal expansion in vivo (129, 131, 143). 
Furthermore, anergic or hypo-responsive OX40+ T cells may be re-activated by OX40 agonists 
(133). OX40 is also constitutively expressed by CD4+Foxp3+ regulatory T cells (Treg) (127). 
Indeed, recent studies have demonstrated that agonist signaling through OX40 inhibits the 
suppressor function of natural Foxp3+ Treg (208), prevents the induction of Treg from CD4+ T 
effector cells (144), and confers resistance to effector cells against Treg-mediated inhibition 
(143). 
To characterize the molecular, cellular, and treatment-associated consequences of OX40 
engagement in the setting of well-established tumors, a novel agonistic reagent directed against 
murine OX40 (OX40 ligand-Fc fusion protein; OX40L-Fc) was recently constructed and 
characterized in vitro (171). We observed that the progressive growth of well-established day 17 
sarcomas was inhibited by a short course of OX40L-Fc therapy, with complete tumor regression 
or extended disease stabilization (i.e. tumor dormancy) observed in the majority of treated 
animals. Comparable findings were obtained in both the MCA205 (H-2b) and CMS4 (H-2d) 
sarcoma models. We noted that i.p. injection of OX40L-Fc induced significant expansion of T 
effector cells in the TDLN, resulting in the accumulation of activated, Type-1 polarized T cells 
in the TME within 10 days of initiating OX40L-Fc therapy. Moreover, our therapy appeared to 
dynamically affect DC and vascular endothelial cells (VEC) in both wild-type and Rag−/− mice 
bearing well-established tumors. The extensive molecular and cellular alterations observed in 
this model strongly support the translation of OX40 agonists into human clinical trials, either as 
single agents or in the context of combinational immunotherapy (6). 
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2.3 MATERIALS AND METHODS 
Mice. Six to ten week old female C57BL/6 (H-2b), B6.129S7-Rag1tm1Mom (Rag−/−; H-2b) and 
BALB/cJ (H-2d) mice were purchased from The Jackson Laboratory and maintained in the 
pathogen-free animal facility in the Biomedical Sciences Tower at the University of Pittsburgh. 
All animal work was done in accordance with a protocol approved by the Institutional Animal 
Care and Use Committee. 
Tumor Establishment. The MCA205 (H-2b) sarcoma cell line was purchased from the 
American Type Culture Collection (ATCC). The CMS4 (H-2d) sarcoma has been described in 
detail previously (209). Cell lines were cultured in complete media (CM; RPMI-1640 
supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 10 mM L-glutamine and 10% 
heat-inactivated fetal bovine serum (all reagents from Life Technologies) in a humidified 
incubator at 37o C and 5% CO2. All cell lines were negative for known mouse pathogens. 
Tumors were established by injection of 5 x 105 tumor cells s.c. into the right flanks of syngeneic 
mice, with tumor size assessed every 3 to 4 days and recorded in mm2. Mice were sacrificed 
when tumors became ulcerated or reached a maximum size of 400 mm2. 
Costimulatory Therapy. Tumor-bearing mice were injected i.p. with 100 µg of OX40L-
Fc or rat IgG isotype control antibody (Sigma-Aldrich) in a total volume of 100 µl PBS on days 
17 and 20 post-tumor inoculation when tumors were approximately 30-50 mm2 in size. The 
mOX40L-Fc fusion protein has been previously described (171). 
Isolation of Tumor, LN and Spleen cells. Single cell suspensions were obtained from 
TDLN as previously described (209). For TIL, tumors were enzymatically digested with 0.1% 
w/v collagenase, 1% w/v hyaluronidase, and 0.1% w/v DNase (all from Sigma), with 
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lymphocytes isolated as buoyant cells after discontinuous density centrifugation as previously 
described (210). 
In Vitro Stimulation (IVS) of T cells. Bulk TIL (n = 1 per group) were restimulated in 
vitro with irradiated (100 Gy) MCA205 cells for 5 days at a T cell-to-tumor ratio of 10:1 in CM 
with 20 U/ml recombinant human IL-2. Recovered T cells were then cultured in media alone (to 
determine background cytokine levels) or with 5µg/ml anti-CD3 (BioLegend) for 72 hours. Cell-
free supernatants were then harvested and assessed for levels of mIFN-γ using a specific OptEIA 
ELISA set (BD Biosciences) according to the manufacturer’s instructions with a lower limit of 
detection of 32.5 pg/ml. Data are reported as the mean ± SD of duplicate determinations. 
RT-PCR. Total RNA was isolated from TIL on days 3, 7, and 10 after the initial 
treatment (day 17 post-tumor inoculation), as indicated, using RNeasy Micro kit (Qiagen), 
according to the manufacturer’s instructions. For semi-quantitative RT-PCR, TIL were cultured 
with 5 µg/ml anti-CD3 (BioLegend) for 24 hours, followed by RNA isolation and cDNA 
preparation using random hexamer primers (Applied Biosciences). PCR was performed using the 
following primer pairs: β-actin (forward), 5’-GGCATCGTGATGGACTCCG-3’; β-actin 
(reverse), 5’-GCTGGAAGGTGGACAGCGA-3’; IFN-γ (forward), 5’-
GAAAGCCTAGAAAGTCTGAATAAC-3’; IFN-γ (reverse), 5’-
ATCAGCAGCGACTCCTTTTCCGCT-3’; IL-10 (forward), 5’-
AGTGGAGCAGGTGAAGAGTGATT-3’; IL-10 (reverse), 5’-
TCATGTATGCTTCTATGCAGTTGATG-3’; T-bet (forward), 5’-
AACCAGCACCAGACAGAGATG-3’; T-bet (reverse), 5’-
TAGAAGAGGTGAGAAGGGGTC-3’; Foxp3 (forward), 5’-GGCCCTTCTCCAGGACAGA-
3’; Foxp3 (reverse), 5’-GCTGATCATGGCTGGGTTGT-3’. Cycling times and temperature 
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were as follows: initial denaturation at 94°C for 2 min (1 cycle), denaturation at 94°C for 30 s, 
annealing at 60-65°C for 30 s and elongation at 72°C for 1 min (35-40 cycles), final extension at 
72°C for 5 min (1 cycle). Following gel electrophoresis, PCR products were imaged and band 
density quantified using LabWorks Software (PerkinElmer). For quantitative RT-PCR, reverse 
transcription and PCR amplification was performed by the University of Pittsburgh’s Genomics 
and Proteomics Core Laboratories (a shared resource). For quantitative analysis of T-bet, IFN-γ, 
and control β-actin, previously published primer pairs were used (211), and cDNA was amplified 
using SYBR Green PCR Master Mix (Applied Biosystems). For quantitative analysis of 
Foxp3, IL-10, and control β-actin, RT2 qPCR Primer Assays (SABiosciences) were used and 
cDNA was amplified using RT2 SYBR Green qPCR Master Mix (SABiosciences). For each 
sample, the cycle threshold (Ct) values for β-actin gene were determined for normalization 
purposes and the ∆Ct between β-actin and T-bet, Foxp3, IFN-γ and IL-10 were calculated. ∆∆Ct 
were calculated to isotype treatment samples. Relative RNA expression for each gene is depicted 
as 2∆∆Ct. 
Confocal Immunofluorescence Staining and Imaging. Tumor tissue was processed and 
sectioned as previously reported (209), followed by immunofluorescence staining and confocal 
microscopy. The following primary antibodies were used for staining sections: rat anti-mouse 
CD31 (BD Biosciences), goat anti-mouse OX40 (Santa Cruz Biotechnology), rat anti-mouse 
OX40 (eBioscience), hamster anti-mouse CD11c (BD Biosciences), rat anti-mouse VCAM-1 
(Santa Cruz Biotechnology), and goat anti-mouse CXCL9 (R&D Systems). The following 
secondary antibodies were used: donkey anti-rat Alexa Fluor 488 (Molecular Probes), donkey 
anti-goat Cy3 (Jackson ImmunoResearch), donkey anti-hamster Alexa Fluor 488 (Molecular 
Probes), donkey anti-rat Cy3 (Jackson ImmunoResearch), goat anti-rat Fab1 fragment Cy3 
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(Jackson ImmunoResearch), and goat anti-rat Alexa Fluor 488 (Molecular Probes). All sections 
were briefly incubated with DAPI (Sigma) and then mounted. Images were acquired using an 
Olympus Fluoview 1000 confocal microscope (Olympus). Isotype control and specific antibody 
images were taken using the same level of exposure on the channel settings. 
Flow Cytometry. Before all stainings, cells were Fc-blocked with anti-CD16/CD32 (BD). 
Single-cell suspensions were stained using the following antibodies: PerCP- and PE-conjugated 
CD4 and CD8, PE-conjugated Gr-1, FITC-conjugated CD80 and CD25, and PerCP-Cy5.5-
conjugated Ki67 (all BD), FITC-conjugated CD27, Class II and F4/80, PE-conjugated CCR7 and 
OX40, and APC-conjugated CD11c, CD44, CXCR3, and CD11b (all eBioscience) or 
appropriate-matched, fluorochrome-labeled isotype control mAb. For Foxp3 intracellular 
staining, CD4+ T cells were surface stained as described above and then further processed using 
an APC anti-mouse/rat Foxp3 Staining kit (eBioscience) according to the manufacturer’s 
instructions. FITC-conjugation of OX40L-Fc was performed using a FITC protein labeling kit 
(Molecular Probes). Cells were analyzed using an LSR II flow cytometer (Beckman Coulter), 
with corollary data assessed using FlowJo software (version 7.6.1; Tree Star, Inc.). 
Statistical Analysis. All comparisons of inter-group means were performed using a two-
tailed Student’s t test, with P values < 0.05 considered significant. 
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2.4 RESULTS 
2.4.1 OX40L-Fc treatment elicits potent anti-tumor activity against well-established 
tumors. 
A novel OX40 agonist, consisting of mOX40L linked to the C-terminus of the Fc fragment of 
immunoglobulin, was recently constructed and shown to be curative in early day 5 (H-2d) Colon 
26 and RENCA tumor models (171). In contrast, an agonist anti-OX40 (OX86) mAb was only 
able to extend median survival by approximately 2 weeks in these models. To determine whether 
OX40L-Fc would be efficacious in a more established and potentially clinically-relevant disease 
model, we treated H-2b mice bearing day 17 MCA205 sarcomas via i.p. injection of 100 µg of 
OX40L-Fc or control rat IgG. A second identical dose was provided three days later. Tumors in 
all control-treated mice grew progressively and exhibited a rapid expansion in size around day 30 
post-inoculation, necessitating euthanasia by day 40 (Figure 1A). In contrast, OX40L-Fc-treated 
mice exhibited reduced, stabilized tumor size by day 27 that was durable through day 40. 
Although OX40L-Fc treatment resulted in the long-term survival of only 13% of treated animals 
(Figure 1B), 50% of this cohort exhibited small (~20-40 mm2) lesions that remained “dormant” 
for more than 6 weeks, before eventually progressing. Growth of representative tumors 
exhibiting dormancy in OX40L-Fc-treated mice is shown in Figure 1C. 
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Figure 1. Systemic OX40L-Fc treatment is therapeutic against well-established tumors in wild-type mice. 
(A) MCA205 sarcomas (n = 8 per group) were injected s.c. into the right flank of C57BL/6 wild-type mice. Mice 
bearing established day 17 tumors (~30 to 50 mm2 in area) were treated i.p. with 100 µg of rat IgG isotype control 
mAb or OX40L-Fc, as indicated. Treatment was repeated on day 20 after tumor inoculation. Tumor areas (mm2) 
were calculated every 3 days, with the data for individual animals reported. (B) Data from Figure 1A are presented 
in a Kaplan-Meier plot. (C) Mean tumor areas ± SD are shown for representative OX40L-Fc-treated mice exhibiting 
tumor dormancy (n = 3), with data obtained from isotype-treated control animals (n = 3) shown for comparison. 
Data are representative of two independent experiments performed. 
 
Similar therapeutic benefits were observed in the CMS4 (H-2d) sarcoma model, where 
over 80% of animals rejected their tumors after OX40L-Fc treatment on days 17 and 20 
(Appendix Figure 1). Despite the superior efficacy observed for OX40L-Fc in the CMS4 model, 
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all remaining data were collected in the MCA205 tumor model due to the tendency of progressor 
CMS4 tumors to ulcerate, necessitating pre-mature euthanasia per IACUC regulations. 
2.4.2 T cell and DC expression of OX40 is elevated in the progressor TME. 
To identify the in situ cellular targets of OX40L-Fc-based therapy, we next assessed OX40 
expression on T cell subsets within the TDLN and the TME of untreated MCA205 tumor-bearing 
mice between days 17 and 20 post-tumor inoculation. While OX40 was barely detectable on 
CD4+Foxp3− and CD8+ T cells in the TDLN, approximately 50% of CD4+Foxp3+ T cells 
expressed OX40 (Figure 2A), consistent with previous reports indicating that OX40 expression 
is restricted to the regulatory subset of resting T cells in peripheral tissues (143). Conversely, 
OX40 expression was up-regulated on all T cell subsets in the untreated TME, including a 
median of over 20% of CD8+ T cells and over 60% of CD4+Foxp3− T cells. 
Because NK and NKT cells can express OX40 under certain conditions (170, 212), we 
hypothesized that non-T cell subsets may also represent targets for interaction with OX40L-Fc in 
the progressor TME. Indeed, OX40 expression was highly up-regulated on 
CD11c+CD11b+ClassIIhi tumor-infiltrating DC (TIDC) when compared to TDLN-localized DC 
(median of 37.6% vs. 2.3% OX40+, respectively; Figure 2B). OX40 was also detected on TIDC 
via confocal immunofluorescence microscopy (Figure 2C). Furthermore, FITC-labeled OX40L-
Fc was found to bind to TIDC, but not to TDLN-localized DC (Figure 2D). These data suggest 
that although CD4+Foxp3+ T cells may represent the exclusive expressors of OX40 in the 
periphery, CD4+Foxp3− and CD8+ T effector cells, as well as DC, contain substantial OX40+ 
populations in the TME, making each of these cell types plausible targets of OX40L-Fc-based 
therapy. 
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Figure 2. T cell and DC expression of OX40 is elevated in the progressive TME in wild-type mice. 
(A and B) Single-cell suspensions (n = 4) were prepared from untreated MCA205 tumors (TME) and tumor-draining 
lymph nodes (TDLN) isolated between days 17 and 20 post-tumor inoculation. (A) Percentages of OX40+ T cells 
among the indicated gated cell populations are shown (left panel). Each symbol corresponds to an individual tumor-
bearing mouse (bar = median value). Representative histograms are depicted (right panel), with percentages of 
OX40+ T cells and mean fluorescence intensity (MFI) of OX40+ T cells indicated. Filled histograms represent cells 
isolated from the TDLN; open histograms represent cells isolated from the TME. (B) Percentages of DC 
(CD11c+CD11b+ClassIIhi) expressing OX40 in the TDLN and TME are reported (bar = median value). (C) 
Untreated MCA205 tumors were isolated between days 17 and 20 post-tumor inoculation, then sectioned, stained 
and analyzed by confocal fluorescence microscopy as described in Materials and Methods. Representative staining 
of DAPI (blue), OX40 (green) and CD11c (red) is shown, with arrows indicating CD11c+OX40+ cells. Inset reflects 
higher power (60x magnification) image. Bars, 10 µm. (D) Representative staining of gated CD11c+CD11b+ DC 
  40 
with FITC-labeled OX40L-Fc. Filled histogram represents cells isolated from the TDLN; open histogram represents 
cells isolated from the TME. Experiments were repeated two times with similar results obtained in each instance. 
2.4.3 T cell-independent enrichment of mature DC expressing the LN-homing receptor 
CCR7 in the TDLN shortly after treatment with OX40L-Fc. 
Given the observed high levels of OX40 expressed by TIDC in untreated tumor-bearing mice, 
we next evaluated how DC populations were altered in response to OX40L-Fc treatment. By day 
3 after the first OX40L-Fc treatment, TIDC expression of the costimulatory molecules CD80 and 
CD86 was augmented (data not shown), and a concordant increase in CD11c+CD11b+ DC within 
the TDLN was observed when compared to isotype mAb-treated control mice (Figure 3A). 
These TDLN DC populations expressed elevated levels of CD80 and the lymph node-homing 
chemokine receptor CCR7 when compared to TDLN isolated from isotype mAb-treated control 
animals (Appendix Figure 2). Moreover, enrichment of DC upon OX40L-Fc treatment was 
similarly observed in the TDLN of Rag−/− mice bearing established MCA205 tumors (Figure 
3B). These data are consistent with the T cell-independent activation/maturation of OX40+ TIDC 
to become competent for trafficking to the TDLN within the initial 3 days of OX40L-Fc-based 
therapy. Longitudinal analysis suggests that treatment-induced migration of TIDC to the TDLN 
persists through day 7 of the therapy period, with a return to control conditions by day 10 (data 
not shown). Such trafficking of activated DC would be anticipated to sponsor the cross-priming 
of anti-tumor T cell responses in the TDLN. We observed no substantial alterations, however, in 
DC frequency or phenotype in non-TDLN (data not shown). 
  41 
 
Figure 3. Longitudinal analysis of TDLN populations following OX40L-Fc treatment. 
MCA205 tumor-bearing wild-type or Rag−/− mice were treated as in Figure 1 and TDLN cells were isolated on day 3 
after treatment with isotype control antibody or OX40L-Fc (n = 4 per group). In A, the percentages and absolute 
numbers (x 104) of CD11c+CD11b+ DC among gated live cells are shown for wild-type mice. Each symbol 
corresponds to an individual animal. The solid line represents the median value. In B, a representative density plot is 
shown, with percentages indicated for CD11c+CD11b+ DC among total TDLN cells isolated from Rag−/− mice. For 
panels C and D, TDLN cells were isolated from wild-type mice on days 3, 7, and 10 after treatment. Graphs show 
absolute numbers (x 105) of CD4+Foxp3− and CD8+ T cells (C) and the percentages of Ki67+ T cells (D). Data are 
representative of results obtained in 2 independent experiments in each case. *, P < 0.05; **, P < 0.01. 
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2.4.4 OX40L-Fc treatment promotes the expansion of TDLN T cells expressing the tissue-
homing Type-1 chemokine receptor CXCR3. 
To assess alterations in the TDLN T cell compartment following OX40L-Fc treatment and TIDC 
trafficking to the TDLN, we harvested TDLN from mice on days 3, 7, and 10 after initiating 
treatment and determined absolute numbers of CD4+Foxp3− and CD8+ T effector cells. Time-
dependent increases in both T cell sub-populations were noted as a consequence of OX40L-Fc 
treatment, with numbers of TDLN T cells peaking at day 7 post-treatment (Figure 3C). Indeed, 7 
days after initiating OX40L-Fc treatment, highly significant up-regulation in expression of the 
proliferation marker Ki67 was observed for both CD4+ and CD8+ T cell subsets within the 
TDLN (P < 0.01; Figure 3D). Although these T cells did not exhibit any alterations in activation 
marker expression (CD25 and CD69; data not shown), both CD4+ and CD8+ T cells expanded 
from OX40L-Fc-treated versus control mAb-treated mice were enriched in the CD44hi phenotype 
at day 7 post-treatment (Appendix Figure 3A), supporting the ability of OX40L-Fc therapy to 
preferentially stimulate memory T cells. 
It has recently been demonstrated that Type-1 polarized CD8+ T cells are effectively 
recruited to tumor sites via CXCR3-mediated chemotaxis in response to the CXCL9-11 
chemokines produced within the TME (33). To determine whether TDLN T cells in OX40L-Fc-
treated animals are differentially competent to migrate to the TME based on this index, we 
assessed CD4+ and CD8+ T cells for their expression of CXCR3 7 days after the initiation of 
therapy. As shown in Appendix Figure 3B, we found that the CXCR3+ sub-population of CD4+ 
and CD8+ T cells was increased after OX40L-Fc versus control mAb treatment. These data 
suggest that OX40 agonist therapy not only stimulates expansion of TDLN T cells, but also 
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licenses these cells for trafficking to peripheral tissue sites in which CXCR3 ligands are 
expressed, such as the TME. 
2.4.5 Tumors become enriched in T effector cells by day 10 following OX40L-Fc 
treatment. 
Based on our observation that maximal numbers of CXCR3+ TDLN T cells occurred by day 7 
after OX40L-Fc treatment, we hypothesized that these transport-competent T cells might then 
infiltrate the TME shortly thereafter. Although increased frequencies of CD4+Foxp3− and CD8+ 
T effector cells were detected in the TME throughout the observation period, a highly significant 
increase versus control mAb-treated animals was noted for CD4+Foxp3− TIL at days 7 and 10 
post-treatment and CD8+ TIL at day 10 post-treatment (P < 0.01; Figure 4A). The change in 
percentages of T effector cells correlated with increases in the number of CD4+Foxp3− and CD8+ 
TIL per gram of tumor tissue (Appendix Figure 4). In order to distinguish between the 
recruitment of T effector cells and in situ T cell expansion within the TME, TIL were analyzed 
for their expression of Ki67. While Ki67 expression was up-regulated by T cells in the TDLN of 
OX40L-Fc-treated mice (Figure 3D), expression of this marker on TIL was not substantially 
altered (Figure 4B), suggesting that T effector cell accumulation in the TME of treated mice is 
most likely attributed to the enhanced recruitment of these cells, rather than to their expansion 
within tumor lesions. 
Despite an elevated frequency of CD4+Foxp3+ T cells being consistently identified in the 
TDLN of OX40L-Fc-treated mice (Appendix Figure 5A), the frequency of these cells in the 
TME was reduced as early as day 3 post-treatment and this level remained low throughout the 
observation period (Appendix Figure 5B), consistent with a recent report (213). Additionally, a 
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decrease in cells exhibiting a myeloid-derived suppressor cell phenotype (CD11b+Gr-1+) was 
observed in the TME, along with a coordinate increase in F4/80+ mature 
monocytes/macrophages between days 7 and 10 post-treatment (Appendix Figure 6). 
 
Figure 4. Accumulation of T effector cells in the TME of wild-type mice by day 10 following OX40L-Fc treatment. 
TME cells were isolated on days 3, 7, and 10 after treatment with isotype control antibody or OX40L-Fc. Graphs 
show percentages of CD4+Foxp3− and CD8+ T cells (A) and percentages of Ki67+ T cells (B). Each symbol 
corresponds to one tumor-bearing mouse. The solid line represents the median value. (C) TIL were isolated on day 
10 after treatment with isotype control antibody or OX40L-Fc. Percentages of CD44hi of CD4+ and CD44hi of CD8+ 
cells are indicated on representative histograms. CD27 was evaluated on gated CD4+ and CD8+ cells, as indicated 
(representative histograms are shown). Open histograms represent cells isolated from isotype control mAb-treated 
mice; filled histograms represent cells isolated from OX40L-Fc-treated mice. Similar data were obtained in two 
independent experiments performed. *, P < 0.05; **, P < 0.01. 
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2.4.6 Tumor infiltrating T cells exhibit a re-activated memory phenotype and are Type-1 
polarized. 
An analysis of the phenotype of TIL on day 10 after OX40L-Fc treatment, at which time T 
effector cell frequencies in the TME peaked, suggested no differential expression of CD25 or 
CD69 versus the control mAb-treated cohort (data not shown). However, the frequency of CD4+ 
and CD8+ TIL expressing high levels of CD44 (CD44hi, antigen-experienced) and low levels of 
CD27 (CD27low, recently-activated) was enriched at this time point (Figures 4C and Appendix 
Figure 7). These phenotypic analyses are consistent with a model in which OX40L-Fc-stimulated 
T cells are expanded in the TDLN by day 7 post-treatment and subsequently infiltrate the TME 
by day 10 post-treatment. 
Because effective cancer immunotherapies have been largely associated with a state of 
Type-1 T cell polarization and an increased T effector cell-to-Treg ratio (214, 215), we next 
examined the polarization status of freshly-isolated TIL on days 3-10 following OX40L-Fc- 
versus control mAb-treatment. Using quantitative RT-PCR, factors associated with Type-1 T cell 
activity (i.e. T-bet and IFN-γ) and those associated with regulatory T cell activity (i.e. Foxp3 and 
IL-10) were assessed for their relative levels of expression. Although minimal alterations were 
observed in the expression of any of these four transcripts on days 3 and 7 post-treatment, by day 
10 post-treatment, at a time when increased frequencies of TIL were observed, transcript levels 
for all 4 gene products were dramatically enhanced in the OX40L-Fc treatment group. (Figure 
5A, upper panels). This is consistent with a recent report by Ruby and colleagues, who propose 
that while all T cell lineages are responsive to OX40 stimulation, the plasticity of the response is 
dependent on the local cytokine milieu (216). By considering the “balance” of polarized T cell 
responses based on a ratio of the effector-to-regulatory gene transcripts, however, we noted that 
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OX40L-Fc treatment skews the balance in favor of Type-1 T cell immunity at all time points 
analyzed (Figure 5A, lower panels). Similar alterations in these transcript ratios were observed in 
anti-CD3-stimulated TIL (Figure 5B). This suggests that although OX40 signaling may not be a 
polarizing event per se, a cytokine milieu appropriate for the preferential expansion of Type-1 
versus regulatory-type immunity exists within the OX40L-Fc-treated TME. 
 
Figure 5. TIL exhibit a Type-1 polarized phenotype. 
TIL were isolated from wild-type mice on days 3, 7, and 10 after treatment with isotype control antibody or OX40L-
Fc. (A) Quantitative RT-PCR was performed on purified RNA (n = 2 per group, pooled) using primers specific for 
murine T-bet, Foxp3, IFN-γ, and IL-10. ∆∆Ct were calculated to day 3 isotype treatment samples and relative RNA 
expression for each gene is depicted as 2∆∆Ct (upper panels). Ratios of T-bet/Foxp3 and IFN-γ/IL-10 are also shown 
(lower panels). Similar data were obtained in two independent experiments performed. (B) TIL were stimulated with 
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anti-CD3 for 24 hours in vitro as outlined in Materials and Methods, with semi-quantitative RT-PCR performed on 
purified RNA (n = 2 per group, pooled) using primers specific for murine T-bet, Foxp3, IFN-γ, and IL-10. Similar 
data were obtained in two independent experiments performed. (C) Isolated TIL were re-stimulated in vitro with 
irradiated MCA205 cells for five days (as described in Materials and Methods). Recovered T cells were then 
stimulated with anti-CD3 for 72 hours and supernatants were assessed for levels of IFN-γ. Data are reported as the 
mean ± SD of duplicate determinations. Similar data were obtained in two independent experiments performed. (D) 
CD4+Foxp3− and CD8+ T effector-to-CD4+Foxp3+ Treg cell ratios were determined by flow cytometry (n = 4 per 
group). Data are representative of three independent experiments performed. *, P < 0.05; **, P < 0.01. 
 
To ensure that alterations in IFN-γ RNA expression correlated with alterations at the 
protein level, TIL were isolated on days 3-10 post-treatment and stimulated in vitro prior to 
analysis of IFN-γ secretion levels by ELISA. Interestingly, TIL production of IFN-γ was not 
elevated, and perhaps even slightly reduced on day 3 after treatment with OX40L-Fc versus 
isotype mAb (Figure 5C). In contrast, TIL isolated 7 and 10 days after initiating OX40L-Fc-
based therapy produced significantly higher levels of IFN-γ protein versus TIL harvested from 
control mAb-treated mice at these same time points. Moreover, when comparing the effector-to-
regulatory balance at the cellular level within the TME, significant increases were observed in 
both the CD4+Foxp3− and CD8+ T effector versus Treg ratios at days 7 and 10 post-treatment (P 
< 0.01; Figure 5D). 
2.4.7 OX40L-Fc treatment renders the TME permissive to Type-1 T cell infiltration via 
modulation of the tumor vasculature. 
In parallel with an increased fraction of CXCR3+ T cells in the TDLN of OX40L-Fc-treated 
mice, CXCL9 (a CXCR3 ligand) was dramatically up-regulated in the TME between days 7 and 
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10 post-treatment (Figure 6A, left panels), indicating that OX40L-Fc therapy redundantly 
promotes TIL trafficking by augmenting chemokine signals in both the periphery and the TME. 
We have also recently reported that effective recruitment of adoptively-transferred Type-1 
polarized CD8+ T cells into the TME requires tumor-associated VEC expression of VCAM-1 
(217). Confocal immunofluorescence microscopy revealed that tumor-associated CD31+ VEC 
rapidly up-regulate (i.e. by day 3) and maintain VCAM-1 expression through day 10 as a 
consequence of treatment with OX40L-Fc (Figure 6B, left panels), suggesting that Type-1 T 
effector cell recruitment into the TME might be further enhanced by OX40L-Fc via additional, 
chemokine-independent mechanisms. Importantly, treatment-associated enhancement of VCAM-
1 and CXCL9 expression by CD31+ VEC was recapitulated in Rag−/− mice (Figures 6A and B, 
right panels), suggesting the T cell-independent nature of these changes. In support of a direct 
effect of OX40L-Fc on VEC within the TME, we detected moderate levels of OX40 expression 
by a subset of CD31+CD11b− VEC in untreated, progressor tumors (Appendix Figure 8). It is 
also important to note that Figure 6A data suggest that additional (non-VEC) stromal cells in the 
TME produce CXCL9 in wild-type, but not Rag-/- mice (most strikingly on day 7 post-treatment 
with OX40L-Fc). Hence, therapeutic production of CXCL9 in the TME appears to result from 
both T cell-dependent and T cell-independent processes. 
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Figure 6. T cell-independent up-regulation of VEC-associated CXCL9 and VCAM-1 in the TME following 
OX40L-Fc treatment. 
MCA205 tumors were isolated from wild-type (left panels) or Rag−/− (right panels) mice and analyzed by confocal 
fluorescence microscopy on the indicated days after treatment with isotype control antibody or OX40L-Fc. In A, 
expression of DAPI (blue), CXCL9/Mig (red), and CD31 (green) is depicted. In B, expression of DAPI (blue), 
CD31 (red) and VCAM-1 (green) is depicted. Bars, 50 µm. 
 
We also observed a pronounced reorganization of the tumor vasculature after OX40L-Fc 
treatment, consistent with what has previously been described as a more “normalized” phenotype 
(111). While CD31+ VEC density increased coordinately with disease progression in the tumors 
of isotype control mAb-treated mice, vessel density in OX40L-Fc-treated tumors was 
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significantly diminished by day 10 post-treatment (Appendix Figure 9A). These alterations in 
vascular density at day 10 post-treatment additionally correlated with a less tortuous and more 
organized (i.e. normalized) morphology of OX40L-Fc- versus control mAb-treated tumor 
vasculature (Appendix Figure 9B), consistent with a phenotype favorable for lymphocyte 
infiltration. 
2.5 DISCUSSION 
In this report, we describe multifaceted anti-tumor activities associated with a novel mOX40L-Fc 
fusion protein when applied in the therapeutic setting against well-established H-2b and H-2d 
sarcomas. When administered i.p. on days 17 and 20 post-tumor inoculation, OX40L-Fc 
treatment inhibited tumor growth, resulting in disease stabilization or complete regression in the 
majority of treated animals. 
In the TDLN of mice bearing well-established MCA205 sarcomas, OX40 expression was 
restricted to CD4+Foxp3+ T cells, whereas CD4+Foxp3− and CD8+ T effector cells, as well as DC 
and potentially VEC, were observed to be OX40+ in the TME. Expression of OX40 has also been 
reported to be up-regulated by T cells in primary tumors, but not in the tumor-free lymph nodes 
of human cancer patients (180). In alternative disease models, T cell up-regulation of OX40 has 
been observed at sites of inflammation during the onset of experimental autoimmune 
encephalomyelitis (218), and within the synovial fluid, but not the peripheral blood of patients 
with rheumatoid arthritis (219). This has been attributed to the influence of inflammatory 
cytokines, including IL-1 and TNF-α (220, 221). Such cytokines could also play a role in up-
regulating the expression of OX40 by tumor-localized DC and VEC in our well-established 
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sarcoma models. Furthermore, 4-1BB, an alternate member of the costimulatory TNFR family 
with structural and functional similarities to OX40, can be expressed by activated DC and 
atherosclerotic endothelia under the appropriate conditions (222, 223). 
Numerous studies have indicated that both CD4+ and CD8+ T effector cells play 
instrumental roles in anti-tumor immunity stimulated by OX40 agonists in vivo (178). Consistent 
with this notion, we observed significant expansion of CXCR3+ TDLN T effector cells on day 7 
after initiating OX40L-Fc-based therapy, followed on day 10 post-treatment by the accumulation 
of re-activated, Type-1 polarized CD4+Foxp3− and CD8+ T cells in the TME. Our data from 
Rag−/− models also now suggest the T cell-independent nature of OX40L-Fc-mediated events, 
including: i.) the rapid and sustained production of CXCL9 and expression of VCAM-1 on VEC 
in established tumors, and ii.) the conversion of OX40+ TIDC into transport-competent APC 
(deduced from the subsequent enrichment of CD11c+CCR7+ myeloid DC in the TDLN by day 3 
post-treatment). Although a recent study has demonstrated a similar enhancement in DC 
trafficking to the TDLN upon treatment with OX40 agonist mAb in an early-stage tumor model, 
this finding was attributed to therapy-mediated suppression of Treg function and to a corollary 
restoration in the migratory capacity of TIDC (172). Instead, based on the constitutive expression 
of OX40 by a sub-population of TIDC in the well-established TME and the preservation of DC 
alterations in Rag−/− mice following OX40L-Fc treatment, these alterations may occur via the 
direct engagement of OX40 on these cells. To unequivocally demonstrate a direct effect of 
OX40L-Fc on TIDC, prospective therapeutic models employing chimeric mice in which only 
DC are genetically deficient in expression of OX40 will be pursued. 
The importance of manipulating the tumor vasculature to attract T cells has recently been 
demonstrated by Quezada and colleagues, who report ICAM and VCAM up-regulation in the 
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TME upon prophylactic Treg cell depletion as well as therapeutic vaccination (Gvax)/anti-
CTLA-4 combination treatment (115), indicating that vascular activation may be achieved 
through several distinct mechanisms. Similar to our data, activation of the tumor vasculature in 
these models correlated with enhanced T cell infiltration, increased T effector-to-Treg cell ratios 
and improved therapeutic efficacy. Our data further suggest that therapy-associated induction of 
chemokines and adhesion molecules that render the TME more permissive to immune cell 
infiltration can be achieved in the absence of T cells. OX40L-Fc could conceivably mediate 
vascular activation in the TME of Rag−/− mice via: i.) direct stimulation of a subset of OX40+ 
VEC, ii.) inflammatory cytokine/chemokine production by OX40+ TIDC, or iii.) the participation 
of alternate inflammatory (i.e. NK among others) effector cells present in these mice. The initial 
effects of nonhematopeoietic and/or innate immune cell subsets in therapy-mediated vascular 
activation, however, are likely to synergize with the effects mediated by T cells in immune 
competent hosts. In our model, for example, initial secretion of inflammatory cytokines (i.e. 
TNF-α) by OX40+ TIDC upon OX40L-Fc treatment may induce CXCL9 and VCAM-1 
expression in the TME, allowing for the recruitment of Type-1 polarized T effector cells that 
produce IFN-γ (a potent inducer of CXCL9 and other angiostatic chemokines), resulting in 
further remodeling of the tumor vasculature and enhanced T cell infiltration. Future studies will 
investigate the validity of this paradigm. 
Based on the tumor growth curves of OX40L-Fc- versus control mAb-treated mice, the 
impact of therapy only becomes apparent by 7-10 days after the initiation of therapy. This is 
consistent with the infiltration of a highly-reactive CD27lowCD44hi CD8+ T effector cell 
population into the TME. As OX40 signaling has been previously shown to enhance recall 
responses and to preferentially expand CD44hi memory T cells upon antigen rechallenge (137, 
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224), this may suggest that OX40L-Fc treatment leads to the expansion of a tumor antigen-
experienced, rather than naïve, T effector cell population in the TDLN, and subsequent 
trafficking of these T cells to the TME. Regardless, these infiltrating T cells appear competent to 
promote tumor regression or to regulate a state of tumor dormancy (i.e. stable disease) in the 
majority of OX40L-Fc-treated animals for a period of several weeks prior to the ultimate 
“escape” of progressor lesions. We are currently investigating whether this late progression event 
results from the erosion of protective anti-tumor T cell responses, the outgrowth of less-
immunogenic tumor cell variants, and/or the reacquisition of aberrant vascular structures in the 
TME (63). If the former mechanism underlies the ultimate failure of OX40L-Fc to induce 
complete tumor rejection, we would anticipate the enhanced benefits of extending the number of 
treatment cycles involving OX40 agonists. 
Overall, the therapeutic benefits demonstrated for OX40L-Fc in our well-established 
sarcoma models strongly supports the continued translation of OX40 agonists, particularly those 
based on a recombinant form of OX40L, into human clinical trials. Moving forward, it will be 
important to better delineate how the various OX40+ target cell populations within the TME (and 
elsewhere) are impacted by OX40-mediated signals in order to select potential co-therapeutic 
agents and to define a strategically-rational schedule for the administration of each modality to 
yield maximal treatment benefit. 
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3.1 ABSTRACT 
Agonistic modalities targeting the costimulatory molecule GITR (glucocorticoid-induced tumor 
necrosis factor receptor) have demonstrated therapeutic benefit in numerous murine tumor 
models. In some reports, anti-tumor efficacy has been attributed to the activation of conventional 
T cells, while in others the antagonism of CD4+Foxp3+ regulatory T cells (Treg) has played a 
more dominant role. Using a novel GITR ligand-Fc fusion protein (GITRL-Fc), we now show 
that GITR stimulation induces regression of well-established day 17 CMS4 (H-2d), but not 
MCA205 (H-2b) sarcomas, with comparable efficacy observed for treatment with an agonist anti-
GITR mAb (DTA-1). To elucidate the reasons for therapeutic failure in the MCA205 model, we 
conducted a longitudinal analysis of cells isolated from the tumor-draining lymph nodes (TDLN) 
and the tumor microenvironment (TME) of GITRL-Fc-treated mice. By day 7 after treatment, a 
significant increase in expansion of both regulatory and effector T cells was observed in the 
TDLN, and by day 10 post-treatment, CD4+Foxp3− and CD8+ T effector cells had accumulated 
in tumors. Importantly, a corresponding decrease in Treg frequencies occurred in the TME, 
resulting in increased effector-to-regulatory T cell ratios. An incomplete activation phenotype 
(i.e. variable up-regulation of activation markers, inconsistent responses to ex vivo stimulation) 
was observed for T cells isolated from the TDLN and TME of GITRL-Fc-treated mice. These 
data suggest that at least in some tumor systems, single modality therapy using GITR agonists 
may prove suboptimal, and that combinational approaches may be warranted. 
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3.2 INTRODUCTION 
Similar to other costimulatory members of the tumor necrosis factor receptor (TNFR) family, 
GITR (glucocorticoid-induced TNFR) is expressed at low levels on resting CD4+Foxp3− and 
CD8+ T cells, but is up-regulated shortly after T cell receptor (TCR) engagement on both naïve 
and antigen-experienced cells (5, 135). Particularly under conditions of low antigen dosing in 
vivo, signals contributed through GITR have been shown to enhance CD4+ and CD8+ T effector 
cell proliferation (225), activation marker expression (151), and production of IFN-γ and IL-10 
upon ex vivo stimulation (226). Furthermore, an established state of T cell anergy can be 
reversed by direct ligation of GITR expressed by hyporesponsive T effector cells (227). 
CD4+Foxp3+ regulatory T cells (Treg) express higher levels of GITR than T effector cells under 
steady state conditions (127), and numerous studies have shown that GITR stimulation can 
inhibit the suppressor function of Tregs (208), or confer resistance of effector cells to Treg-
mediated inhibition (154, 159). 
Based on the ability of GITR agonists to simultaneously antagonize regulatory circuits 
and directly activate T cells, GITR represents an attractive target in cancer immunotherapy. 
Indeed, GITR-targeting therapeutics have demonstrated potent anti-tumor effects in numerous 
pre-clinical models (6, 165). Although an expanding literature supports the anti-tumor efficacy of 
GITR agonists, the mechanism(s) through which such reagents function has not been 
comprehensively studied. A number of studies suggest that both CD4+ and CD8+ T cell subsets 
play instrumental roles in productive anti-tumor immunity induced by GITR stimulation in vivo. 
CD4+ T cell helper activity, which serves to “license” DC-mediated priming (29) and to support 
cytotoxic T lymphocyte (CTL) function via IFN-γ production (40), can be augmented by GITR-
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targeted therapy (191). Furthermore, direct engagement of GITR enhances primary anti-tumor 
CD8+ T cell responses (228), provides activation signals to hyporesponsive tumor-primed CTL 
(189), and renders effector T cells resistant to Treg-mediated inhibition (191, 229). Additional 
reports suggest that the therapeutic efficacy of GITR agonists is predicated primarily on the 
ability of such agents to mitigate Treg-sponsored immunosuppression (i.e. impairment of Treg 
infiltration into tumor sites and loss of Foxp3 expression by Treg following GITR engagement) 
(230). 
A novel agonistic reagent directed against murine GITR (GITR ligand-Fc fusion protein; 
GITRL-Fc) was recently constructed and shown to effectively mediate tumor regression in mice 
bearing day 6 Colon 26 (H-2d) tumors to a degree that was comparable to that observed for 
treatment with agonist anti-GITR mAb (DTA-1) (192). To more rigorously assess the 
translational potential of this reagent in a more advanced disease setting, we allowed MCA205 
(H-2b) sarcomas to establish and grow progressively until day 17, at which point a short course 
of systemic GITRL-Fc therapy was initiated. Although CD4+Foxp3− and CD8+ T effector cell 
expansion in the TDLN and increased effector-to-regulatory T cell ratios in the TME were 
induced by GITRL-Fc versus isotype mAb control treatment, complete regression of these well-
established MCA205 tumors occurred in only a minority of treated animals. Interestingly, T cells 
isolated from the TDLN and TME of treated mice did not appear to be fully activated by GITRL-
Fc administration, as determined by an analysis of cell phenotype and ex vivo functionality. 
Based on these data, we believe that therapies based on GITR agonists alone may provide only 
limited clinical benefit in the advanced cancer setting. 
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3.3 MATERIALS AND METHODS 
Mice. Six to ten week old female C57BL/6 (H-2b) and BALB/cJ (H-2d) mice were purchased 
from The Jackson Laboratory and maintained in the pathogen-free animal facility in the 
Biomedical Sciences Tower at the University of Pittsburgh. All animal work was done in 
accordance with a protocol approved by the Institutional Animal Care and Use Committee. 
Tumor Establishment. The MCA205 (H-2b) sarcoma cell line was purchased from the 
American Type Culture Collection (ATCC). The CMS4 (H-2d) sarcoma has been described in 
detail previously (209). Cell lines were cultured in complete media (CM; RPMI-1640 
supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 10 mM L-glutamine and 10% 
heat-inactivated fetal bovine serum (all reagents from Life Technologies) in a humidified 
incubator at 37o C and 5% CO2. All cell lines were negative for known mouse pathogens. 
Tumors were established by injection of 5 x 105 tumor cells s.c. into the right flanks of syngeneic 
mice, with tumor size assessed every 3 to 4 days and recorded in mm2 (as the product of 
orthogonal diameters). Mice were sacrificed when tumors became ulcerated or reached a 
maximum size of 400 mm2. 
Costimulatory Therapy. Tumor-bearing mice were injected i.p. with 100 µg of rat IgG 
isotype control antibody (Sigma-Aldrich), mGITRL-Fc, or rat anti-GITR mAb (DTA-1) in a total 
volume of 100 µl PBS on days 17 and 20 post-tumor inoculation when tumors were 
approximately 30-50 mm2 in size. The agonist anti-GITR mAb and the GITRL-Fc fusion protein 
(192) have been previously described. 
Isolation of Tumor, LN and Spleen cells. Single cell suspensions were obtained from 
spleen and TDLN as previously described (209). For tumor-infiltrating lymphocytes (TIL), 
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tumors were enzymatically digested with 0.1% w/v collagenase, 1% w/v hyaluronidase, and 
0.1% w/v DNase (all from Sigma), with lymphocytes isolated as buoyant cells after 
discontinuous density centrifugation as previously described (210). 
In Vitro Stimulation (IVS) of T cells. Bulk cells isolated from the TDLN or TME of 
isotype mAb- or GITRL-Fc-treated mice were stimulated ex vivo with 5µg/ml anti-CD3 
(BioLegend) in CM with 20 U/ml recombinant human IL-2 for 72 hours. Cell-free supernatants 
were then harvested and assessed for levels of mIFN-γ using a specific OptEIA ELISA set (BD 
Biosciences) according to the manufacturer’s instructions. This assay had a lower detection limit 
of 32.5 pg/ml. Data are reported as the mean ± SD of duplicate determinations. 
RT-PCR. Total RNA was isolated from TIL on days 3, 7, and 10 after the initial 
treatment (day 17 post-tumor inoculation), as indicated, using RNeasy Micro kit (Qiagen), 
according to the manufacturer’s instructions. For quantitative RT-PCR, reverse transcription and 
PCR amplification was performed by the University of Pittsburgh’s Genomics and Proteomics 
Core Laboratories (a shared resource). For quantitative analysis of T-bet, IFN-γ, and control β-
actin, previously published primer pairs were used (211), and cDNA was amplified using 
SYBR Green PCR Master Mix (Applied Biosystems). For quantitative analysis of Foxp3, IL-
10, and control β-actin, RT2 qPCR Primer Assays (SABiosciences) were used and cDNA was 
amplified using RT2 SYBR Green qPCR Master Mix (SABiosciences). For each sample, the 
cycle threshold (Ct) values for the control β-actin gene were determined for normalization 
purposes and the ∆Ct between β-actin and T-bet, Foxp3, IFN-γ and IL-10 were calculated. ∆∆Ct 
were calculated to isotype treatment samples. Relative RNA expression was determined for each 
gene (2∆∆Ct) and ratios of T-bet/Foxp3 and IFN-γ/IL-10 expression are reported. 
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Confocal Immunofluorescence Staining and Imaging. Tumor tissue was processed and 
sectioned as previously reported (209), followed by immunofluorescence staining and confocal 
microscopy. For analysis of GITR expression by T cell subsets, sections were incubated with rat 
anti-mouse CD4 or CD8α (both BD Biosciences), in combination with goat anti-mouse GITR 
(Santa Cruz Biotechnology). After washing, sections were incubated with donkey anti-rat Alexa 
Fluor 488 and donkey anti-goat Cy3 (both Jackson ImmunoResearch). For analysis of GITR 
expression by Foxp3+ T cells, sections were treated with Alexa Fluor 488-conjugated rat anti-
mouse Foxp3 (eBioscience), in combination with goat anti-mouse GITR, followed after washing 
by staining with donkey anti-goat Cy3. All sections were briefly incubated with DAPI (Sigma) 
and then mounted. Images were acquired using an Olympus Fluoview 1000 confocal microscope 
(Olympus). Isotype control and specific antibody images were taken using the same level of 
exposure on the channel settings. 
Flow Cytometry. Before all stainings, cells were Fc-blocked with anti-CD16/CD32 (BD). 
Single-cell suspensions were stained using the following antibodies: PerCP-, FITC-, PE- and 
APC-conjugated CD4 and CD8α (all BD), PE-conjugated GITR and CD25 (both eBioscience), 
or appropriate-matched, fluorochrome-labeled isotype control mAb. For Ki67 intracellular 
staining, T cells were surface stained as described above, fixed, and incubated with PerCP-
Cy5.5-conjugated Ki67 (BD), according to the manufacturer’s instructions. For Foxp3 
intracellular staining, CD4+ T cells were surface stained as described above and then further 
processed using an APC-conjugated anti-mouse/rat Foxp3 Staining kit (eBioscience) according 
to the manufacturer’s instructions. Cells were analyzed using an LSR II flow cytometer 
(Beckman Coulter), with corollary data assessed using FlowJo software (version 7.6.1; Tree Star, 
Inc.). 
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Statistical Analysis. All comparisons of inter-group means were performed using a two-
tailed Student’s t test, with P values < 0.05 considered significant. 
3.4 RESULTS 
3.4.1 GITRL-Fc is marginally effective against well-established tumors. 
Hu and colleagues generated two different GITRL-Fc constructs (#175-2 and #178-14) that vary 
by five amino acids (192). From pilot studies, it was determined that construct #175-2 
demonstrated greater in vivo activity than construct #178-14 in our sarcoma models (data not 
shown). As a result, GITRL-Fc construct #178-14 was not used in any further therapeutic 
experiments. We treated C57BL/6 mice bearing day 17 MCA205 sarcomas via i.p. injection of 
100 µg of GITRL-Fc (construct #175-2), agonist anti-GITR mAb (DTA-1) or control rat IgG. A 
second identical dose was provided three days later. When compared to the control mAb 
treatment cohort, GITRL-Fc- and DTA-1-treated mice exhibited a moderate delay in tumor 
progression, with complete tumor regression observed in a small minority of cases (Figure 7A). 
Overall, long-term tumor-free survivors were observed in only 17% of cases treated with 
GITRL-Fc (Figure 7B). 
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Figure 7. Limited therapeutic efficacy of GITRL-Fc against well-established tumors. 
(A) MCA205 sarcomas (n = 6 per group) were injected s.c. into the right flank of C57BL/6 mice. Mice bearing 
established day 17 tumors (~30 to 50 mm2 in area) were treated i.p. with 100 µg of rat IgG isotype control mAb, 
agonist GITR mAb (DTA-1) or GITRL-Fc, as indicated. Treatment was repeated on day 20 after tumor inoculation. 
Tumor areas (mm2) were calculated every 3 days, with the data for individual animals reported. The number of 
tumor-free mice at day 80 of the total treated mice is indicated. (B) Data from Figure 7A are presented in a Kaplan-
Meier plot. Data are representative of two independent experiments performed. 
 
To assess the therapeutic benefits of GITRL-Fc in an alternative sarcoma model, BALB/c 
mice bearing established CMS4 tumors were treated on days 17 and 20 post-tumor inoculation 
with isotype mAb control, DTA-1, or GITRL-Fc. In contrast to the minimal anti-tumor efficacy 
demonstrated by both GITR agonists in the MCA205 tumor model, DTA-1- or GITRL-Fc-based 
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therapies resulted in tumor eradication (Figure 8A) and prolonged survival (Figure 8B) in 80% 
and 100% of treated animals, respectively. When taken together, these data indicate that the 
therapeutic activity of GITR agonists against established sarcomas may be recipient strain- 
and/or tumor cell line-specific. 
 
Figure 8. Tumor rejection induced by GITRL-Fc in an alternative sarcoma model. 
(A) BALB/c mice bearing day 17 CMS4 sarcomas (n = 6 per group) were treated as in Figure 7. Tumor areas (mm2) 
were calculated every 3 days, with the data for individual animals reported. The number of tumor-free mice at day 
80 out of the number of treated mice is indicated. (B) Data from Figure 8A are presented in a Kaplan-Meier plot. 
Data are representative of two independent experiments performed. 
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3.4.2 GITR is constitutively expressed by Tregs, but up-regulated by TIL. 
GITR has been reported to be expressed at low levels on resting T effector cells and at high 
levels by Tregs and activated T effector cells (5). Indeed, bulk CD4+ T cells from naïve C57BL/6 
mice can either express low or high levels of GITR (Figure 9A), and upon further analysis, 
CD4+GITRhi cells from these naïve mice were also Foxp3+ (data not shown). We next assessed 
frequencies of GITRhi T cells within the TDLN and the TME of untreated MCA205 tumor-
bearing mice between days 17 and 20 post-tumor inoculation, as these cells may represent 
primary cellular targets of GITRL-Fc-based therapy. Nearly 100% of CD4+Foxp3+ T cells from 
the TDLN of tumor-bearing mice express high levels of GITR, while only very low frequencies 
of CD4+Foxp3− and CD8+ T cells were GITRhi (Figure 9B). Because the TME provides a large 
depot of antigen that can be presented to TIL by both professional and non-professional APCs 
(231), we hypothesized that antigen-dependent up-regulation of GITR on T cells is likely to be 
most profound within progressing tumors. Although CD4+Foxp3+ T cells from the TDLN and 
TME expressed comparably high levels of GITR, GITR expression was slightly up-regulated on 
CD8+ T cells and substantially up-regulated on CD4+Foxp3− T cells, including a median of over 
10% of CD8+ T cells and over 40% of CD4+Foxp3− T cells that were GITRhi (Figure 9B). GITR 
was also detected on CD4+Foxp3− and CD4+Foxp3+ T cells in established MCA205 tumors via 
confocal immunofluorescence microscopy (Figure 9C). These results suggest that 
CD4+Foxp3+GITRhi T cells in the TDLN and TME, in addition to CD4+Foxp3−GITRhi and 
CD8+GITRhi T cells in the TME, likely represent principal targets of GITRL-Fc in the tumor-
bearing host. 
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Figure 9. Differential GITR expression patterns by T cells in TDLN and tumors. 
(A) Representative GITR staining on CD4+ T cells isolated from the spleens of naïve mice. GITR+ cells are divided 
into GITRhi and GITRlow populations, as indicated. (B) Single-cell suspensions (n = 4) were prepared from untreated 
MCA205 tumors (TME) and tumor-draining lymph nodes (TDLN) isolated between days 17 and 20 post-tumor 
inoculation. Percentages of GITRhi T cells among the indicated gated cell populations are shown. Each symbol 
corresponds to an individual tumor-bearing mouse (bar = median value). (C) Untreated MCA205 tumors were 
isolated between days 17 and 20 post-tumor inoculation, then sectioned, stained and analyzed by confocal 
fluorescence microscopy as described in Materials and Methods. Representative staining of DAPI (blue), GITR 
(red), and either CD4, CD8 or Foxp3 (all in green) is shown, with CD4+GITR+ cells appearing yellow due to co-
staining overlays. Experiments were repeated two times with similar results obtained in each instance. 
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3.4.3 GITRL-Fc administration induces the expansion of both effector and regulatory T 
cells in the TDLN. 
To evaluate treatment-dependent alterations in the TDLN T cell compartment of tumor-bearing 
mice, C57BL/6 mice bearing established MCA205 sarcomas were treated with isotype mAb 
control or GITRL-Fc as in Figure 7. TDLN from these mice were then harvested on days 3, 7, 
and 10 after initiating treatment. Despite low expression of GITR by T effector cells in the 
TDLN (Figure 9B), absolute numbers of both CD4+Foxp3− and CD8+ T cells increased 
significantly by day 7 after GITRL-Fc treatment initiation, with a median of 17.1 (± 3.9) x 105 
CD4+Foxp3− and 25.7 (± 9.8) x 105 CD8+ TDLN cells were observed in GITRL-Fc-treated mice 
versus 10.9 (±4.4) x 105 CD4+Foxp3− and 9.9 (± 2.7) x 105 CD8+ TDLN cells in control mAb-
treated animals (Figure 10A). To determine whether this expanded T effector cell population in 
the TDLN of GITRL-Fc-treated mice was a result of in situ proliferation or influx from 
peripheral tissues, expression of the proliferation marker Ki67 was assessed in CD4+CD25− and 
CD8+ T cells. Since a strong correlation between CD25 and Foxp3 expression was consistently 
observed (data not shown), CD25 served as a surrogate marker in some experiments to 
distinguish between effector and regulatory CD4+ T cell phenotypes. At day 7 post-treatment, 
Ki67 was up-regulated by both CD4+CD25− and CD8+ T cells in the TDLN of GITRL-Fc-treated 
mice versus isotype mAb-treated controls (Figure 10B), suggesting that T effector cells expand 
within the TDLN in response to GITRL-Fc treatment. 
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Figure 10. Expansion of T effector cells in the TDLN peaking at day 7 following GITRL-Fc treatment. 
MCA205 tumor-bearing mice were treated as in Figure 7. (A) TDLN cells were isolated on days 3, 7, and 10 after 
treatment initiation with isotype control antibody or GITRL-Fc (n = 3-6 per group). Absolute numbers (x 105) of 
CD4+Foxp3− and CD8+ T cells are reported as the mean ± SD. For panels B and C, TDLN cells were isolated on day 
7 after treatment with isotype control antibody or GITRL-Fc. Ki67 was evaluated on gated CD4+CD25− and CD8+ 
cells (B) and CD25 was evaluated on gated CD8+ cells (C). Representative histograms are shown. Filled histograms 
represent cells isolated from isotype control mAb-treated mice; open histograms represent cells isolated from 
GITRL-Fc-treated mice. Percentages of Ki67+ or CD25+ cells per treatment are indicated. (D) TDLN cells were 
isolated on day 7 after treatment with isotype control antibody or GITRL-Fc and stimulated with anti-CD3 for 72 
hours. Supernatants were then assessed for levels of IFN-γ, with data reported as the mean ± SD of duplicate 
determinations. Values correspond to one animal (representative of two total) per group. Data are representative of 
results obtained in 2 independent experiments in each case. *, P < 0.05; **, P < 0.01. 
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Given that GITRL-Fc administration was able to induce proliferation of TDLN T cells, 
we assessed these cells for additional indicators of cell activation, including enhanced cytokine 
secretion (151, 226, 232). Unexpectedly, neither CD4+Foxp3− (data not shown) or CD8+ T cells 
(Figure 10C) in the TDLN expressed elevated levels of the activation marker CD25 after 
treatment with GITRL-Fc versus isotype mAb. Similarly, these T cells did not exhibit alterations 
in control level expression of CD69, CD44, or CD27 (data not shown). In contrast, in vitro 
stimulation of TDLN cells isolated from GITRL-Fc-treated mice resulted in enhanced IFN-γ 
production compared to isotype mAb-treated controls (Figure 10D). This suggests that although 
T effector cells expanded in the TDLN upon GITRL-Fc treatment, comprehensive activation of 
T cells under these conditions did not occur. 
Consistent with previous reports using the agonist mAb DTA-1 (189, 191), highly-
significant increases in CD4+Foxp3+ T cell frequencies were identified in the TDLN of GITRL-
Fc-treated mice (P < 0.01; Figure 11A). Increased frequencies of CD4+CD25+ T cells were 
associated with elevated Ki67 expression (Figure 11B), indicating that these cells were actively 
proliferating within the TDLN as a consequence of GITRL-Fc treatment. Moreover, when 
comparing effector-to-regulatory T cell ratios within the TDLN, GITRL-Fc-mediated decreases 
were observed in both the CD4+Foxp3− and CD8+ T effector versus Treg ratios throughout the 
observation period (Figure 11C). As a consequence, despite the capacity of GITRL-Fc to 
promote proliferation of CD4+Foxp3− and CD8+ T effector cells, our data suggest these 
conditions result in the preferential expansion of Tregs (and suboptimal anti-tumor immunity) in 
the TDLN of tumor-bearing mice. 
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Figure 11. Rapid and sustained proliferation of regulatory T cells in the TDLN upon GITRL-Fc treatment. 
(A) TDLN cells were isolated on days 3, 7, and 10 after treatment with isotype control antibody or GITRL-Fc (n = 
3-6 per group). Percentages of CD4+Foxp3+ T cells among gated live cells are reported as the mean ± SD. (B) Ki67 
was evaluated on gated CD4+CD25+ cells isolated from the TDLN on day 7 after treatment (representative 
histogram is shown). Filled histogram represents cells isolated from isotype control mAb-treated mice; open 
histogram represents cells isolated from GITRL-Fc-treated mice. Percentages of Ki67+ cells per treatment are 
indicated. (C) TDLN cells were isolated on days 3, 7, and 10 after treatment with isotype control antibody or 
GITRL-Fc. CD4+Foxp3− and CD8+ T effector-to-CD4+Foxp3+ Treg cell ratios were determined by flow cytometry. 
Similar data were obtained in two independent experiments performed. *, P < 0.05; **, P < 0.01. 
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3.4.4 Incompletely-activated T effector cells accumulate in the TME by day 10 following 
GITRL-Fc treatment. 
Given these data, we next hypothesized that T effector cell expansion in the TDLN upon GITRL-
Fc treatment would correlate with increased frequencies of these cells in the TME, particularly 
since GITR was highly-expressed by CD4+Foxp3− and CD8+ TIL (Figure 9B). Notable increases 
in T effector cell frequencies versus control mAb-treated animals, however, were only detected 
in the TME at day 10 post-treatment, with highly-significant increases identified in the CD8+ T 
cell subset (9.6 ± 2.7% versus 5.6 ± 1.8%, respectively; P < 0.01; Figure 12A). Upon further 
examination, Ki67 expression was unaltered in CD4+CD25− and CD8+ TIL isolated from 
GITRL-Fc- versus isotype mAb-treated mice (data not shown), suggesting that T effector cell 
accumulation in the TME of treated mice is most likely a result of enhanced recruitment of these 
cells, rather than TIL expansion in situ. The cumulative data from our longitudinal analyses are 
consistent with a model in which T effector cells expand in the TDLN, peaking at day 7 after 
GITRL-Fc treatment (Figure 10A), followed shortly thereafter (i.e. day 10 post-treatment) by 
infiltration/recruitment of these cells into the TME (Figure 12A). 
Similar to the unique activation phenotype we observed in the TDLN following GITRL-
Fc therapy, CD4+Foxp3− (data not shown) and CD8+ T cells (Figure 12B) in the TME of GITRL-
Fc-treated animals up-regulated the activation marker CD25, but failed to secrete elevated levels 
of IFN-γ upon in vitro stimulation (Figure 12C). Additionally, no substantial alterations in CD69, 
CD44, or CD27 expression were observed (data not shown). Although the activation phenotypes 
were not identical in the TDLN and TME (unchanged CD25 expression but enhanced IFN-γ 
production in the former, enhanced CD25 expression but unchanged IFN-γ production in the 
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latter), T cells isolated from either the TDLN or TME of treated mice did not appear to be fully 
activated as a consequence of GITRL-Fc-based therapy. 
 
Figure 12. Accumulation of incompletely-activated T effector cells in the TME by day 10 following GITRL-Fc 
treatment. 
(A) TME cells were isolated on days 3, 7, and 10 after treatment with isotype control antibody or GITRL-Fc (n = 3-
6 per group). Percentages of CD4+Foxp3− and CD8+ T cells among gated live cells are reported as the mean ± SD. 
(B) CD25 was evaluated on gated CD8+ cells isolated from the TME on day 10 after treatment (representative 
histogram is shown). Filled histogram represents cells isolated from isotype control mAb-treated mice; open 
histogram represents cells isolated from GITRL-Fc-treated mice. Percentages of CD25+ cells per treatment are 
indicated. (C) TME cells were isolated on day 10 after treatment with isotype control antibody or GITRL-Fc and 
stimulated with anti-CD3 for 72 hours. Supernatants were then assessed for levels of IFN-γ, with data reported as the 
mean ± SD of duplicate determinations. Values correspond to one animal (representative of two total) per group. 
Data are representative of results obtained in 2 independent experiments in each case. *, P < 0.05; **, P < 0.01. 
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3.4.5 Decreased Treg frequencies results in an elevated effector-to-regulatory T cell ratio 
in the TME following GITRL-Fc treatment. 
In accordance with two recent reports (230, 232), the frequency of CD4+Foxp3+ T cells in the 
TME of GITRL-Fc-treated mice was reduced as early as day 3 post-treatment, and remained low 
throughout the observation period (Figure 13A), despite elevated frequencies of these cells 
observed in the TDLN (Figure 11A). Simultaneous increases in CD4+Foxp3− and CD8+ TIL 
frequencies and decreases in CD4+Foxp3+ T cell frequencies after GITRL-Fc treatment resulted 
in enhanced effector-to-regulatory T cell ratios in the TME (Figure 13B). This observation is of 
particular therapeutic importance, as effective cancer immunotherapies have been largely 
associated with enhanced intratumoral T effector cell-to-Treg ratios (215). To ensure that 
alterations in the effector-to-regulatory balance at the cellular level correlated with alterations at 
the RNA level, factors associated with Type-1 T cell activity (i.e. T-bet and IFN-γ) and those 
associated with regulatory T cell activity (i.e. Foxp3 and IL-10) were assessed for their relative 
levels of expression in TIL isolated on days 3-10 following GITRL-Fc- versus control mAb-
treatment. Using quantitative RT-PCR, moderate increases in the effector-to-regulatory gene 
transcript ratios were observed for both transcription factors (T-bet/Foxp3) and cytokines (IFN-
γ/IL-10) (Figure 13C). Together, these data indicate that GITRL-Fc treatment skews the balance 
between the effector and regulatory arms of immunity within the TME in favor of Type-1 T cell 
immunity at both the cellular and molecular level. 
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Figure 13. Increased effector-to-regulatory T cell ratios in the TME following GITRL-Fc treatment. 
TME cells were isolated on days 3, 7, and 10 after treatment with isotype control antibody or GITRL-Fc. (A) 
Percentages of CD4+Foxp3+ T cells among gated live cells are reported as the mean ± SD (n = 3-6 per group). Data 
are representative of two independent experiments performed. (B) CD4+Foxp3− and CD8+ T effector-to-
CD4+Foxp3+ Treg cell ratios were determined by flow cytometry. Similar data were obtained in two independent 
experiments performed. (C) Quantitative RT-PCR was performed on purified RNA (n = 2 per group, pooled) using 
primers specific for murine T-bet, Foxp3, IFN-γ, and IL-10. Relative RNA expression was determined for each gene 
(2∆∆Ct) and ratios of T-bet/Foxp3 and IFN-γ/IL-10 expression, normalized to isotype control treatment, are depicted. 
*, P < 0.05; **, P < 0.01. 
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3.5 DISCUSSION 
The anti-tumor efficacy of GITR agonists, particularly the anti-GITR mAb DTA-1, has already 
been widely explored in numerous murine tumor models (190, 232-234), although the vast 
majority of these treatment regimens were initiated within the first week following tumor cell 
inoculation. Due to the well-recognized failure of many immunotherapies that demonstrated 
safety and efficacy in the pre-clinical setting to bridge the gap between mice and men (163, 201), 
a priority of this study was to utilize an animal model with enhanced translational relevance. 
Schreiber and colleagues have described that tumor cell inoculation causes coagulation necrosis 
and acute inflammation during the first 10 days, creating the illusion of an established, palpable 
tumor (202). Only by about 2 weeks post-tumor inoculation have such artifacts been replaced by 
a mature tumor stroma, making these tumors indistinguishable from non-transplanted primary 
tumors. Following these recommendations, we began a short course of GITRL-Fc or DTA-1 
therapy at day 17 post-tumor inoculation, when MCA205 tumors were approximately 50 mm2 in 
size. 
These tumors contained aberrant vascular structures, a hallmark of solid tumors (111), 
and high frequencies of mature (F4/80+CD11b+) and immature (Gr-1+CD11b+) myeloid cells 
(typically 15% and 20% of total TME cells, respectively) (data not shown). Using this salient 
disease model, we were able to show that both GITRL-Fc and DTA-1 therapy can induce the 
regression of well-established day 17 CMS4 (H-2d), but not MCA205 (H-2b) sarcomas. Two 
potential explanations exist for this discrepancy. First, despite injection of equivalent numbers of 
either MCA205 or CMS4 tumor cells, MCA205 tumors were approximately 50 mm2 in size at 
the time of treatment initiation, whereas CMS4 tumors were slightly smaller (30 mm2), 
indicating that MCA205 grows more aggressively and may be inherently more difficult to treat 
  75 
than CMS4. In this regard, the TME of MCA205 and CMS4 may also be differential with regard 
to the balance of protective versus suppressive immunity, mechanisms by which these immune 
cell populations mediate their functions, and general responsiveness to immunotherapy. 
However, our recent results employing an OX40 agonist-based therapy, which successfully 
treated both day 17 MCA205 and CMS4 models (235), would argue against this latter point. 
Second, given the appreciated immune polarization differences between C57BL/6 (more Type-1 
biased) and BALB/c (more Type-2 biased) strains of mice (236), the mechanism of action for 
therapeutic GITR agonists could be somewhat different when comparing the MCA205 versus 
CMS4 models. In order to identify the factors underlying strain-specific responsiveness to GITR-
based therapy, we are currently investigating the molecular and cellular alterations associated 
with GITRL-Fc treatment in greater detail in the CMS4 model. 
A longitudinal analysis was conducted to address the consequences of GITRL-Fc therapy 
on T cell subsets in the TDLN. Based on the observation that CD4+Foxp3+ T cells in the TDLN 
express high levels of GITR, it was not unexpected that these cells exhibited rapid and sustained 
proliferation in response to GITRL-Fc treatment. Previous studies have found that Tregs 
expanded in vitro as a result of GITR stimulation lose their suppressor activity (208), suggesting 
that expanded CD4+Foxp3+ TDLN T cells in our model may be functionally silenced by GITRL-
Fc treatment. Although T effector cells in the TDLN were primarily GITRlow in phenotype, by 
day 7 following GITRL-Fc treatment we observed significant increases in the absolute numbers 
of both CD4+Foxp3− and CD8+ T cells that express elevated levels of Ki67. Because 
CD4+Foxp3+ T cells are the only plausible target for GITRL-Fc in the TDLN, T effector cell 
expansion at this site is most likely attributable to GITR-mediated inactivation of Treg function 
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and subsequent restoration of the proliferative capacity of TDLN T effector cells. This 
hypothesis is being tested in ongoing studies. 
Notably higher frequencies of CD4+Foxp3− and CD8+ T effector cells exhibited a GITRhi 
phenotype within MCA205 tumor lesions when compared to the TDLN, and GITRL-Fc 
treatment resulted in elevated frequencies of these cells by day 10 post-treatment. This did not 
correlate with an up-regulation of Ki67 expression in T cells, however, suggesting that T cell 
accumulation in the tumors of treated mice is principally the result of enhanced recruitment—
presumably from the TDLN—and not proliferation of these T cells within TME. In contrast, 
CD4+Foxp3+ T cell frequencies were significantly diminished in the TME of GITRL-Fc-treated 
mice, consistent with the recent observations of Cohen and colleagues in a B16 melanoma model 
(230). Through adoptive transfer experiments and the utilization of Foxp3-GFP transgenic mice, 
they were able to convincingly show that DTA-1 treatment both inhibits Treg recruitment into 
tumors and down-regulates Foxp3 expression in tumor-localized Treg. One or both of these 
mechanisms likely plays a role in the GITRL-Fc-induced decrease in CD4+Foxp3+ TIL observed 
in our sarcoma model. 
It has been previously shown in murine tumor and autoimmune disease models that GITR 
stimulation is sufficient to support T cell activation and the development of T effector function in 
vivo (151, 191, 226, 232), whether as a result of direct engagement of GITR on these cells or via 
the inactivation of bystander Tregs. Surprisingly, we found that T cells isolated from the TDLN 
and TME of GITRL-Fc- versus control mAb-treated animals were not activated to the extent that 
would be expected from these previous reports. Differences between experimental models, such 
as variations in GITR agonist dosing schedules and routes of administration, may be responsible 
for these seemingly contrasting findings. Furthermore, one must also consider that previous 
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studies have primarily used the agonist mAb DTA-1, while we have employed a recombinant 
version of the natural GITR ligand, which may convey at least slightly different signals into 
GITRhi target cells. 
Importantly, in contrast to many former models, GITR-based therapy in our study was 
not initiated until tumors became well-established, in accordance with the stringent definition 
established by Schreiber et al. (202). Particularly in the setting of progressive disease, numerous 
regulatory mechanisms are responsible for maintaining immune tolerance in the tumor-bearing 
host. First, tumor-specific T cells can be rendered anergic or hyporesponsive if priming occurs 
under suboptimal conditions in the TDLN (74, 76). Moreover, efficiently-primed T cells can lose 
effector function upon infiltration of tumor lesions as a result of defective TCR signaling (81). In 
addition to these T cell-intrinsic mechanisms of suppression, T effector cell activity can also be 
inhibited extrinsically by Tregs and myeloid-derived suppressor cells (MDSC), both of which 
can be found at high frequencies in the TDLN and TME (102, 104, 237). Perhaps it is not 
surprising then if GITRL-Fc as a monotherapy, at least in the MCA205 tumor model, is unable to 
counteract this plethora of immunosuppressive factors in order to elicit robust T cell activation. 
Overall, the apparent heterogeneous efficacy of single modality GITR agonist treatment 
in our tumor models suggests that uniform therapy benefits may be best observed using 
combinational treatment regimens. Reagents that allow complete T cell activation, such as T cell 
checkpoint blockade inhibitors (i.e. anti-CTLA-4 and anti-PD-1), represent logical co-therapies 
for combination with GITR agonists (238-240). Indeed, a recent report showed that anti-CTLA-
4/anti-GITR mAb combination treatment provides improved benefits, such as the regression of 
150 mm2 s.c. CT26 colon carcinomas. However, treatment was initiated at day 4 day post-tumor 
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inoculation in this study, at which point a mature TME would not be in place (232). We are 
currently evaluating such treatment options in our day 17 sarcoma models. 
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4.0  SUMMARY & INTERPRETATIONS 
4.1 PROPOSED MODEL 
Despite similarities in the structure, surface expression, and downstream signaling pathways of 
the T cell costimulatory molecules OX40 and GITR (5), our findings demonstrate that OX40 and 
GITR agonists exhibit variable therapeutic efficacy in the setting of established tumors and 
function through subtly distinct immunologic mechanisms. While a short course of OX40L-Fc or 
GITRL-Fc therapy elicited potent anti-tumor immunity against day 17 CMS4 (H-2d) sarcomas, 
resulting in over 80% tumor-free survival, treatment with either of these costimulatory agonists 
was only able to induce MCA205 (H-2b) tumor rejection in less than 10% of treated mice. 
Notably, though, 50% of OX40L-Fc-treated mice exhibited small, barely palpable lesions that 
remained “dormant” for more than 6 weeks, before eventually progressing, while animals that 
didn’t initially reject their tumors upon GITRL-Fc treatment (approximately 80%) succumbed to 
progressive disease by day 50 post-tumor inoculation. Therefore, although overall survival 
against MCA205 tumors was equivalent in OX40L-Fc- and GITRL-Fc-treated animals, 
progression-free survival was considerably enhanced by the OX40 agonist. 
Similar expression patterns of OX40 and GITR were observed on T cells isolated from 
untreated tumor-bearing mice. Consistent with the existing literature, CD4+Foxp3+ Tregs were 
observed to constitutively express both costimulatory molecules (127), while CD4+Foxp3− and 
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CD8+ T effector cells within tumor lesions, but not the TDLN, were found to up-regulate OX40 
and GITR expression. Unexpectedly, however, OX40 was highly up-regulated on 
CD11c+CD11b+ClassIIhi tumor-infiltrating DC (TIDC). Although DC expression of OX40 had 
not been previously described, 4-1BB, an additional member of the costimulatory TNFR family, 
can be expressed by activated DC (223). In our preliminary studies, GITR did not appear to be 
up-regulated by TIDC (unpublished data). Since an exhaustive characterization of OX40 and 
GITR expressing cells in tumor-bearing mice was not conducted, we cannot rule out the 
possibility that alternative cell subsets represent additional targets of OX40- and GITR-based 
therapies. 
Through our longitudinal evaluation of OX40L-Fc-dependent alterations in the TDLN 
and TME of wild-type and T cell-deficient mice (Rag−/−), we were able to characterize a series of 
sequential cellular and molecular events that likely contribute to the potent anti-tumor efficacy 
displayed by this reagent (Figure 14A). As early as day 3 post-treatment, accumulation of 
mature, CCR7+ DC was observed in the TDLN, in addition to coordinate up-regulation of 
chemokine and adhesion molecule expression by endothelial cells (VEC) in the TME. Both of 
these events occurred in a T cell-independent manner and are likely a direct result of OX40 
ligation on these cells, as DC, and potentially VEC, were observed to be OX40+ in the TME. The 
secondary phase of this response, starting approximately 7 days after treatment, involved 
profound expansion of CXCR3+CD44hi T effector cells, which may be a consequence of: i.) 
enhanced cross-priming by activated, TDLN-infiltrating DC, ii.) direct engagement of OX40 on 
these cells, and/or iii.) inactivation of TDLN CD4+Foxp3+ Treg (see discussion below). Finally, 
by day 10 post-treatment, Type-1 polarized T cells that secrete high levels of IFN-γ and exhibit a 
re-activated memory phenotype had accumulated in the tumors. 
  81 
 
Figure 14. Pleiotropic and sequential effects of OX40L-Fc and GITRL-Fc treatment in tumor-bearing mice. 
Shaded upper area represents the tumor microenvironment, unshaded lower area represents the TDLN. (A) OX40L-
Fc transmits maturation and migration signals into OX40+ DC and, independently of T cells, induces CXCL9 and 
VCAM-1 expression by OX40+ VEC (1). Myeloid DC accumulate in the TDLN and express elevated levels of 
CD80 and CCR7 in a T cell-independent manner (2). CXCR3+CD44hi T effector cells proliferate within the TDLN 
(3). Activated T effector cells are recruited to and infiltrate the TME, facilitated by treatment-dependent CXCL9 and 
VCAM-1 up-regulation and vascular normalization (4). (B) T effector cells proliferate within the TDLN, but exhibit 
a partially activated phenotype (1). Incompletely-activated T effector cells are recruited to and infiltrate the TME 
(2). (C) Either OX40L-Fc or GITRL-Fc treatment induces rapid and sustained proliferation of CD4+Foxp3+ Tregs in 
the TDLN, while diminished frequencies of these cells in the TME were observed throughout the observation period 
following treatment with either of the costimulatory agonists. 
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Similar to OX40L-Fc treatment, T effector cells expanded within the TDLN of GITRL-
Fc-treated mice at day 7 post-treatment (Figure 14B). Contrary to in vivo OX40 stimulation, 
however, GITR signaling was unable to fully activate these cells. Some indicators of activation 
were present (i.e. enhanced IFN-γ production versus isotype-treated controls upon ex vivo 
stimulation), whereas others were not (i.e. no changes in CD69, CD44, or CD27 expression). As 
in the OX40L-Fc treatment model, T effector cells expressing low levels of Ki67 accumulated in 
the TME by day 10 following GITRL-Fc treatment, suggesting that this event is most likely 
attributed to the enhanced recruitment of these cells, rather than to their expansion within tumor 
lesions. As in the TDLN of these animals, however, suboptimal activation of TIL was observed 
in response to GITRL-Fc administration. At this point, it is not clear why OX40L-Fc is capable 
of inducing more robust T cell activation compared to GITRL-Fc, although it could easily be 
hypothesized that the ability or inability of these reagents, respectively, to stimulate DC plays an 
important role. In other words, by stimulating DCs to migrate from the TME to the TDLN, 
OX40L-Fc treatment provides both signals 1 and 2 to TDLN T cells, while in the GITRL-Fc 
treatment model, the amount of tumor antigen being presented to TDLN T cells at the time of 
GITR costimulation is insufficient to allow complete T cell activation. Although preliminary, 
these comparative results suggest that the most therapeutically efficacious costimulatory agonists 
will be capable of harnessing both innate and adaptive arms of the immune system. 
Given the low levels of OX40 and GITR expression on CD4+Foxp3− and CD8+ TDLN T 
effector cells, the observation that these cells proliferate profoundly in the TDLN of both 
OX40L-Fc- and GITRL-Fc-treated mice was slightly unexpected. In the OX40L-Fc treatment 
model, it could be postulated that TCR stimulation by TDLN-infiltrating DC at day 3 post-
treatment induces OX40 up-regulation on T cells by day 7, at which point they can respond to 
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OX40L-Fc stimulation and proliferate accordingly. This is consistent with the observation that 
OX40 expression by T cells peaks approximately 3 days following TCR engagement (5). 
However, GITRL-Fc therapy induced similar levels of TDLN T effector cell expansion (without 
the corresponding DC alterations), suggesting that DC stimulation may be necessary for 
costimulatory therapy-mediated activation, but not proliferation, of T effector cells. 
An alternative, and more plausible, explanation is that T cell expansion in the TDLN of 
treated mice is a consequence of OX40L-Fc- and GITRL-Fc-mediated disruption of the 
regulatory T cell compartment. Indeed, a common effect of both OX40- and GITR-based 
therapies was rapid and sustained proliferation of Tregs in the TDLN (Figure 14C). This was not 
surprising, though, based on the observation that CD4+Foxp3+ T cells in the TDLN express high 
levels of OX40 and GITR. It has been previously demonstrated that in vitro stimulation of Tregs, 
which are naturally anergic, induces proliferation of these cells, but also abrogates their 
suppressor activity (241), suggesting that expanded CD4+Foxp3+ TDLN T cells in our model 
may be functionally silenced by both OX40L-Fc and GITRL-Fc treatment. This impairment of 
Treg functionality would hypothetically restore the proliferative capacity of TDLN T effector 
cells. Future studies should address the suppressive activity of CD4+Foxp3+ TDLN T cells 
isolated from treated mice. 
Interestingly, despite profound expansion of CD4+Foxp3+ T cells in the TDLN of animals 
treated with either OX40 or GITR agonists, the frequency of these cells in the TME was reduced 
as early as day 3 post-treatment and this level remained low throughout the observation period 
(Figure 14C). Although the reason(s) for these contradictory effects of costimulatory treatment 
on CD4+Foxp3+ T cells in the TDLN versus the TME are presently undefined, this remains an 
active area of investigation. In both OX40L-Fc and GITRL-Fc treatment models, however, the 
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coordinate increase of T effector cells and decrease in Tregs in the TME resulted in skewing of 
the intratumor balance between the effector and regulatory arms of immunity in favor of Type-1 
T cell immunity, at both the cellular and molecular (i.e. mRNA) level. Importantly, elevated 
intratumoral T effector cell-to-Treg ratios are associated with favorable prognosis in both mice 
and humans (215, 242). 
4.2 COSTIMULATORY COMBINATIONS 
Based on our observation that T cells isolated from the TDLN and TME of OX40L-Fc-treated 
mice up-regulated CD44 expression and produced significantly higher levels of IFN-γ upon in 
vitro stimulation versus cells harvested from control mAb-treated mice (235), we hypothesized 
that addition of OX40L-Fc to our GITRL-Fc treatment regimen would overcome the limitations 
of GITRL-Fc monotherapy (i.e. impaired T cell activation) and elicit synergistic anti-tumor 
effects. In a pilot study, C57BL/6 mice bearing established MCA205 sarcomas were treated on 
days 17 and 20 post-tumor inoculation with isotype mAb control, GITRL-Fc, OX40L-Fc, or the 
combination of GITRL-Fc/OX40L-Fc. Upon assessment of progression-free survival, OX40L-
Fc, with or without GITRL-Fc, as compared with GITRL-Fc alone, demonstrated marginally 
improved therapeutic benefit. Although preliminary, these data suggest that the efficacy of 
OX40L-Fc was not improved by the addition of GITRL-Fc. As hypothesized, however, the 
addition of OX40L-Fc moderately enhanced the anti-tumor efficacy of GITRL-Fc. This may be 
attributable to superior DC and/or T cell activation mediated by OX40L-Fc, but not GITRL-Fc, 
therapy. Future experiments will explore the molecular and cellular alterations associated with 
GITRL-Fc/OX40L-Fc combination therapy. To our knowledge, OX40 and GITR dual 
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costimulation has not previously been studied in vitro or as a therapy regimen in preclinical 
tumor models. Therefore, the therapeutic potential of combinational OX40L-Fc/GITRL-Fc 
treatment should not yet be dismissed, as the lack of synergistic activity observed in this pilot 
study may be specific to our tumor model and/or dosing schedule.  
Despite these results, alternative combinations of costimulatory signals, most notably 
OX40/4-1BB dual costimulation, have been shown by other groups to elicit synergistic T cell 
activity. Combinations of 4-1BB and OX40 agonists have been investigated in pre-clinical tumor 
models by numerous groups (243, 244). In one case, all mice bearing late-stage hepatic 
metastases died within 50 days post-tumor inoculation following treatment with either 4-1BB or 
OX40 monotherapies, whereas a 21.4% survival rate at day 180 was observed in the two agent-
based design (173). More recently, Dubrot and colleagues demonstrated that subcutaneous 
injection of hybridomas that secrete both anti-4-1BB and anti-OX40 mAbs were therapeutically 
superior to treatments using hybridomas that produced only one of these antibodies (245). Upon 
evaluation of the mechanism underlying such synergistic effects, it was determined that in vitro 
4-1BB costimulation was sufficient to drive clonal expansion of CD8+ T cells, but that 
acquisition of full Tc1 effector function required coordinate 4-1BB & OX40 triggering (138). 
Although it is tempting to draw comparisons between these data and our own (i.e. GITR signals, 
potentially akin to 4-1BB signals, induce T cell proliferation, but OX40 stimulation is necessary 
for optimal activation), further analysis of the mechanisms supporting superior efficacy of dual 
OX40/GITR costimulation is clearly warranted. Cumulatively, however, these data indicate that 
approaches integrating multiple costimulatory agonists, particularly those incorporating 
activators of the 4-1BB and OX40 costimulatory pathways, hold significant potential in the 
treatment of malignant disease. 
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4.3 COSTIMULATORY AGONISTS IN THE ADJUVANT SETTING 
In accordance with our findings that OX40L-Fc enhances the immunostimulatory capacity of 
TIDC, one would hypothesize that certain combinational strategies would further exploit the 
beneficial role of DC in OX40-based therapy. Indeed, a synergistic relationship between soluble 
OX40L and GM-CSF, an important DC mobilization factor, has been previously demonstrated 
(169). Furthermore, provision of Toll-like receptor agonists that support DC maturation and 
function may also prove beneficial when administered in parallel with OX40 agonists. In support 
of this notion, intratumoral injection of CpG oligodeoxynucleotides, which bind TLR9 expressed 
by DC and other APC, was found to elicit synergistic anti-tumor immunity upon combinational 
treatment with an agonist OX40 mAb (246). 
Since the immune-stimulating properties of costimulatory TNFR agonists, including 
those targeting OX40, GITR, and 4-1BB, are short-lived and rely on the pre-existence of tumor-
primed T cells in the tumor-bearing host, the therapeutic benefit of these treatment modalities 
will likely be optimized when used in combination with alternate forms of cancer therapy (6). 
For example, addition of recombinant IL-12 or IL-12 gene therapy to TNFR regimens has 
proven to be an effective combination, likely via its coordinate promotion of both innate and 
adaptive Type-1 immune responses. Several reports suggest that 4-1BB-mediated therapy is 
synergistically enhanced when combined with IL-12 gene therapy (247-250). It has been 
proposed that IL-12 initially activates NK cells to secrete IFN-γ, inducing DC to up-regulate 4-
1BB and mature into efficient antigen presenting cells upon administration of 4-1BB agonist co-
therapy (248). If NK cell-produced IFN-γ is also capable of inducing OX40 up-regulation by 
DC, it is highly likely that combinational OX40L-Fc and IL-12 therapy will demonstrate 
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synergistic anti-tumor efficacy. Recombinant IL-12 was recently found to enhance OX40 agonist 
therapy in a T cell-intrinsic manner, although additional therapeutic contributions from innate 
immune cells were not assessed in this study (251). Novel combinational regimens incorporating 
alternative cytokines that promote T effector cell survival and function is also highly 
recommended based on the cumulative data from our lab and others. As an example, IL-15 has 
recently been shown to up-regulate GITR expression on CD8+ T cells, while IL-7-mediated up-
regulation of OX40 was observed in CD4+ T cells, leading in both cases to an expanded T cell 
memory pool (135). However, to our knowledge the combination of GITR agonists and IL-15 or 
OX40 agonists and IL-7 has not been studied as a therapy regimen in pre-clinical tumor models. 
One could also readily postulate combinational costimulatory agonist protocols that 
would improve the efficacy of adoptively transferred (i.e. ex vivo expanded or TCR-engineered) 
anti-tumor T cells into the TME. A unique strategy employed by Carl June and colleagues 
consists of genetically engineering T cells to express antibody-based external receptors and 
cytosolic regions that contain TCR and CD28 intracellular signaling domains. These “chimeric 
antigen receptors,” or CARs, bind molecules expressed on the surface of tumor cells in an MHC-
unrestricted manner. Notably, CAR-expressing T cells modified to contain the 4-1BB signaling 
domain displayed prolonged survival in vivo and superior therapeutic efficacy compared to cells 
lacking the 4-1BB signaling component (252). Furthermore, as numerous studies suggest that 
tumor-specific T cells are rendered non-responsive upon infiltration of the tumor 
microenvironment (206), a reasonable approach to re-activate such T cells would be to conjugate 
costimulatory agonists to tumor-targeting antibodies. For example, Zhang et al. demonstrated 
that 4-1BBL conjugated to TNT-3, a nuclear antigen present in necrotic tumor cell debris, 
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prolongs survival of tumor-bearing mice versus animals treated with an untargeted 4-1BBL 
construct (253). 
Since TNFR engagement occurs in an antigen-independent manner, provision of signal 1 
(tumor antigen) by vaccination would allow therapeutic costimulation to preferentially enhance 
the development of specific anti-tumor T cells. In other words, by integrating both passive and 
active immunotherapeutic strategies, perhaps coadministration of costimulatory agonists and 
cancer vaccines represents the combinational approach with greatest therapeutic potential. Two 
independent groups effectively treated tumor-bearing mice with vaccines consisting of tumor 
cells transduced to express the Fv fragment of agonistic 4-1BB mAb, leading to enhanced tumor-
specific immunity as a result of the coordinate provision of cognate antigen and costimulation by 
these engineered APC (254, 255). In addition, GM-CSF-transduced tumor cell vaccines can 
synergize with OX40 stimulation by preferentially enhancing the development of tumor-specific 
immunity (175). Moreover, B16 tumor-bearing mice treated with a control TRP-2-presenting DC 
vaccine succumbed to progressive tumor growth by day 50, whereas vaccination with similar DC 
that were engineered to secrete an agonist GITR mAb resulted in 60% survival by day 100 (256). 
An alternative approach that is conceptually similar to active vaccination involves the promotion 
of “immunogenic” tumor cell death by chemotherapy, radiotherapy, or engagement of the 
apoptotic TNFR family member DR5 (TRAIL receptor) on tumor cells. Indeed, these cytotoxic 
regimens appear to yield synergistic benefits when combined with 4-1BB (257-259), OX40 
(260), and GITR (261) agonist therapies. In a recent study with particular relevance to our 
OX40L-Fc treatment model, it was reported that conjugation of tumor antigen to 4-1BBL 
allowed specific targeting of 4-1BB-expressing DC, resulting in enhanced tumor antigen uptake 
and cross-presentation (262). Therefore, manipulation of our OX40L-Fc reagent to serve as a 
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vehicle for tumor antigen delivery to OX40+ TIDC would, at least in theory, simultaneously 
provide tumor antigen and OX40-mediated activation signals to these DC. The cumulative data 
presented here and by others indicate that TNFR-targeting therapeutics, administered as a 
monotherapy or in combinational regimens, possess high potential for the treatment of cancer, 
and it is anticipated that these modalities will shape the design of cancer immunotherapies in the 
coming years. 
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APPENDIX 
 
Appendix Figure 1. Systemic OX40L-Fc treatment: CMS4 tumor model. 
CMS4 BALB/c sarcomas (n = 6 per group) were injected s.c. into the right flank. Mice bearing established day 17 
tumors (~30 to 50 mm2 in area) were treated i.p. with 100 µg of rat IgG isotype control antibody or OX40L-Fc, as 
indicated. Treatment was repeated on day 20 after tumor inoculation. Tumor areas (mm2) were calculated every 3 
days, with the data for individual animals (left panels) and mean tumor areas ± SD (right panel) depicted. Data are 
representative of two independent experiments performed. ***, P < 0.001. 
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Appendix Figure 2. Up-regulation of CD80 and CCR7 expression on DC in the TDLN upon OX40L-Fc treatment. 
MCA205 tumor-bearing mice were treated on day 17 after tumor inoculation with isotype control antibody or 
OX40L-Fc and TDLN cells were isolated on day 3 after treatment. CD80 and CCR7 expression were evaluated on 
gated CD11c+CD11b+ DC. Representative histograms (right panel) and quantification (left panel) are shown. Filled 
histograms represent cells isolated from isotype control mAb-treated mice; open histograms represent cells isolated 
from OX40L-Fc-treated mice. One representative out of two independent experiments is depicted. *, P < 0.05; **, P 
< 0.01. 
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Appendix Figure 3. Phenotype of TDLN T cells on day 7 following OX40L-Fc treatment. 
(A and B) TDLN cells were isolated on day 7 after treatment with isotype control antibody or OX40L-Fc. (A) 
Representative histograms (right panel) and quantification (left panel) of CD44hi (A) and CXCR3+ (B) T cells are 
shown. (A) Open histograms represent cells isolated from isotype control mAb-treated mice; filled histograms 
represent cells isolated from OX40L-Fc-treated mice. (B) Filled histograms represent cells isolated from isotype 
control mAb-treated mice; open histograms represent cells isolated from OX40L-Fc-treated mice. Data are 
representative of two independent experiments performed. *, P < 0.05; **, P < 0.01. 
  93 
 
Appendix Figure 4. Longitudinal analysis of T effector cell numbers in the TME upon OX40L-Fc treatment. 
TME cells were isolated on days 3, 7, and 10 after treatment with isotype control antibody or OX40L-Fc. Absolute 
numbers (x 103) of CD4+Foxp3− and CD8+ TIL per gram of tumor are shown. 
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Appendix Figure 5. Longitudinal analysis of CD4+Foxp3+ T cell frequencies upon OX40L-Fc treatment. 
(A) TDLN and (B) TME cells were isolated on days 3, 7, and 10 after treatment with isotype control antibody or 
OX40L-Fc. Percentages of CD4+Foxp3+ T cells among gated live cells are shown. Data are representative of three 
independent experiments performed. *, P < 0.05; **, P < 0.01. 
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Appendix Figure 6. Alterations in CD11b+ monocyte populations following OX40L-Fc treatment. 
TME cells were isolated on days 3, 7, and 10 after treatment with isotype control antibody or OX40L-Fc. (A) 
Representative staining of CD11b and Gr-1 on gated live cells is shown along with percentages of CD11b+Gr-1+ 
cells. (B) Representative staining of CD11b and F4/80 on gated live cells is shown along with percentages of 
CD11b+F4/80+ cells. The experiment was repeated two times with similar results. 
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Appendix Figure 7. Phenotype of TIL on day 10 following OX40L-Fc treatment. 
TME cells were isolated on day 10 after treatment with isotype control antibody or OX40L-Fc. Percentages of 
CD44hi and CD27+ T cells are shown. Data are representative of two independent experiments performed. *, P < 
0.05; **, P < 0.01. 
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Appendix Figure 8. Moderate OX40 expression by CD31+CD11b−  vascular endothelial cells in the TME. 
(A and B) Single-cell suspensions were prepared from untreated MCA205 tumors (TME) resected between days 17 
and 20 post-tumor inoculation. (A) Representative staining of OX40 on gated CD31+CD11b− endothelial cells. 
Filled histogram represents control isotype staining. Percentages of OX40+ cells are indicated. The experiment was 
repeated two times with similar results. (B) Representative staining of gated CD31+CD11b− endothelial cells with 
FITC-labeled OX40L-Fc. Filled histogram represents control isotype staining. Percentages of OX40L-Fc+ cells are 
indicated. The experiment was repeated two times with similar results. (C) Untreated MCA205 tumors were 
sectioned, stained and analyzed by confocal microscopy (as described in Materials and Methods). Representative 
staining of DAPI (blue), OX40 (red), and CD31 (green) is shown. Samples were analyzed by confocal microscopy 
with a 60x objective. Bar, 10 µm. 
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Appendix Figure 9. Normalized phenotype of tumor vasculature upon OX40L-Fc treatment. 
MCA205 tumors were sectioned, stained and analyzed by immunofluorescence microscopy on days 3, 7, and 10 
after treatment with isotype control antibody or OX40L-Fc. (A) The percentage of CD31+ vessels per high-power 
field (HPF) within a representative tumor was quantified by Metamorph software. For each tissue section, 10 images 
were captured from non-overlapping image field areas. The percentage of CD31+ cells was calculated as follows: 
(CD31+ pixels per field / total pixels per field) x 100. **, P < 0.0001. (B) Tumor sections were single-stained for 
CD31. Samples were analyzed by immunofluorescence microscopy with a 20x objective and black and white 
images were acquired. Bar, 50 µm. 
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